The Messenger is a publication that is used to notify you of changes to your benefit package. Such notifications, in combination with your Summary Plan Description (SPD) booklet and Schedule of Benefits, form your complete SPD. Attached you will find a compilation of Messenger notifications from the winter 2017-2018 issue, arranged chronologically by topic. It is vital that you read all notifications within a topic to ensure that you are aware of the latest changes. Your SPD will continue to be updated by new issues of the Messenger.
# TABLE OF CONTENTS

- **INTRODUCTION – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ........................................... 1
- **GENERAL EXCLUSIONS AND LIMITATIONS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** .............................................................................................................. 1
- **ELIGIBILITY - MCTWF ACTIVES PLAN** ......................................................................................... 1
- **ELIGIBILITY - MCTWF RETIREES PLAN** ....................................................................................... 3
- **ELIGIBILITY - MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ................................. 6
- **MEDICAL BENEFITS - MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ...................... 7
- **PRESCRIPTION DRUG BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ......................................................................................................................... 13
- **VISION BENEFITS - MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ......................... 28
- **DEATH BENEFITS – MCTWF ACTIVES PLAN** ............................................................................... 30
- **DEATH BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ......................... 30
- **ACCIDENTAL DEATH AND DISMEMBERMENT BENEFITS – MCTWF ACTIVES PLAN** ........... 30
- **ASSIGNMENT, SUBROGATION AND REIMBURSEMENT – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ........................................................................................................ 30
- **COORDINATION OF BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** .......................... 31
- **HOW TO FILE A CLAIM – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ............. 31
- **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN** ........................................................................................................ 32
INTRODUCTION – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

In early March, the newly revised Summary Plan Description (SPD) booklet, dated November 2015, was mailed to all MCTWF Actives Plan and MCTWF Retirees Plan participant households. If the SPD booklet (and/or the subsequently mailed Schedule of Benefits) was not received, the Fund will mail it to you at your request. You also may access the SPD booklet and your Schedule of Benefits on the Fund’s website at www.mctwf.org, from the Summary Plan Description page. To search the SPD booklet for a specific topic, use your search option and enter a key word or phrase.

GENERAL EXCLUSIONS AND LIMITATIONS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

On-the Job Injury or Illness Benefit Exclusion Revision – Spring 2016

Effective May 5, 2016, the Fund’s Summary Plan Description booklet, under General Exclusions and Limitations, has been revised in part to state: “The following are not covered under the MCTWF Actives Plan and MCTWF Retirees Plan: Accidental injury or illness arising in the course of employment.”

Motor Vehicle Accident Related Personal Injury Claims – Spring 2017

For Michigan Residents – Updated Rule

Plan participants and their eligible dependents who reside in the State of Michigan generally are not eligible for medical, prescription drug, or weekly accident and sickness benefits for motor vehicle accident related injuries or illnesses. This is due to Michigan’s no-fault automobile insurance law, which requires insurers to provide unlimited health care benefits to any person suffering an accidental injury or illness as a result of a motor vehicle accident within the United States, its territories and possessions or in Canada. Effective May 4, 2017, upon the submission of proof that (1) such payable benefits have been denied (for reasons other than non-payment of policy) and (2) all rights to appeal or otherwise dispute such denial to the auto insurance carrier have been exhausted, the Plan will provide scheduled benefits upon execution of and compliance with the MCTWF Assignment, Subrogation and Reimbursement Agreement.

For Non-Michigan Residents - Clarification

Plan participants and their eligible dependents who reside outside of the State of Michigan are eligible for MCTWF medical, prescription drug, or weekly accident and sickness benefits for motor vehicle accident related injuries or illnesses only to the extent that claims resulting from the accident are in excess of the greater of (1) the required insurance coverage or other financial protection required under applicable state law, or (2) the benefit limits of any other insurance under which the individual is entitled to coverage. Upon the submission of proof that such responsibility has been met, or benefits have been paid or denied (and if denied, that all rights to appeal or otherwise dispute the denial have been exhausted), MCTWF will provide scheduled benefits in excess thereof, upon execution of, and compliance with, the MCTWF Assignment, Subrogation and Reimbursement Agreement. MCTWF will not coordinate with any other plan or insurance carrier in this regard.

ELIGIBILITY – MCTWF ACTIVES PLAN

Adult Dependent Children Up to Age 26 – New Open Enrollment Window – Fall 2015

In accordance with the Affordable Care Act, MCTWF has made coverage available to all dependent adult children through the end of their 26th birthday month. Except for those children who already were covered or became covered under MCTWF’s rules on or after February 27, 2011, eligibility for coverage on or after April 1, 2011 has been contingent upon submission to MCTWF of an Adult Child Coverage Application for Enrollment form.

The Trustees have authorized another enrollment period for those adult children, beginning November 1, 2015 and ending December 16, 2015, to permit eligibility for coverage commencing on or after January 1, 2016 (contingent upon the eligibility of the child’s parent/participant and only if the child’s age is less than 26 at that time). To enroll, an Adult Child Coverage Application for Enrollment form must be fully filled out and received by MCTWF between November 1, 2015 and December 16, 2015. This form is available on the Forms page of MCTWF’s website at www.mctwf.org or by contacting MCTWF’s Member Services Call Center. Please note that the Application must be timely submitted regardless of whether the adult child’s participant/parent is eligible for coverage at the time of submission of the Application. If and when that participant/parent resumes covered employment, the adult child’s eligibility will commence.
Adult Dependent Children Up to Age 26 – New Open Enrollment Window – Fall 2016

In accordance with the Affordable Care Act, MCTWF has made coverage available to all dependent adult children through the end of their 26th birthday month.

Except for those children who already were covered or became covered under MCTWF’s rules on or after February 27, 2011, eligibility for coverage on or after April 1, 2011 has been contingent upon submission to MCTWF of an Adult Child Coverage Application for Enrollment form.

The Trustees have authorized another enrollment period for those adult children, beginning November 1, 2016 and ending December 31, 2016, to permit eligibility for coverage commencing on or after January 1, 2017 (contingent upon the eligibility of the child’s parent/participant and only if the child’s age is less than 26 at that time).

To enroll, an Adult Child Coverage Application for Enrollment form must be fully completed and received by MCTWF between November 1, 2016 and December 31, 2016. This form is available on the Forms page of MCTWF’s website at www.mctwf.org, or by contacting MCTWF’s Member Services Call Center. Please note that the Application must be timely submitted regardless of whether the adult child’s participant/parent is eligible for coverage at the time of submission of the Application. If and when that participant/parent resumes covered employment, the adult child’s eligibility will commence.

Dependent Eligibility for Wards of Guardians – Fall 2016

Effective September 29, 2016, the MCTWF Actives Plan definition of Dependent has been expanded to include minor children whose legal guardian is either a MCTWF covered participant or his spouse.

Benefit Bank Weeks Renewal – Winter 2017-2018

We are pleased to announce that the Trustees have renewed MCTWF’s standard benefit bank week program for SOA, Key 1, Key 1a, Key 1b, Key 2, Key 2a, Key 2b, Key 2c, Key 2d, Key 3, and Key 3a medical benefit packages for the 36 month period commencing April 1, 2018 as follows:

- Eligible participants who are actively employed on or after April 1, 2018, will be allotted six benefit bank weeks for use during the period April 1, 2018 through March 31, 2021 during periods in which they are not actively employed. However, no benefit bank week coverage is available in the event that the participant quits his employment.
- Benefit bank week coverage includes the medical benefits, and any prescription drug, dental and vision benefits provided for in the participant’s active benefit package. No Weekly Accident and Sickness, Total and Permanent Disability, or Death (or Accidental Death & Dismemberment) benefits will be available when incurred during the period covered by benefit bank weeks.
- Participants who are not actively employed on March 31, 2018 and who are receiving coverage due to their remaining benefit bank week allotment for the 2015 through 2018 period will continue to be covered until their remaining benefit bank weeks are exhausted, or, if earlier, upon their return to active employment. Once contributions are received with regard to their resumption of active employment, they will receive a new allotment of six benefit bank weeks for use through March 31, 2021.

Survivor Health Benefits – SPD Clarification – Winter 2017-2018

The following rewrite of the “Eligibility – Initial and Ongoing” subsection of the “Actives Survivor Health Benefits” section of the MCTWF SPD booklet (Sec. 2.1(m)) adds language (as bolded below) that was inadvertently omitted from the published SPD booklet:

Eligibility - Initial and Ongoing

- Upon receipt of notification of the death of a participant who had Active Coverage on the date of his death, the Fund will notify the participant’s Survivors of their automatic eligibility for Survivor Health Benefits following the exhaustion of any remaining benefit bank coverage, for a maximum period (including the benefit bank coverage period) of 36 months following the coverage week in which the participant died. (*However, if at the time of death the deceased participant’s employer has ceased to maintain Fund benefits for the deceased participant’s MCTWF Actives Plan participating group, his survivors will not be eligible for Survivor Health Benefits.) Each Survivor, in the alternative, may elect COBRA continuation coverage.
For each Survivor who does not elect COBRA continuation coverage, Survivor Health Benefits eligibility will continue as follows:

- For the surviving spouse, for the earlier of 36 months or –
  - remarriage; or
  - enrollment in the MCTWF Retirees Plan (Note: the spouse may defer enrollment until timely expiration of her Survivor Health Benefits coverage, but must comply with the Fund’s rules for timely application for MCTWF Retirees Plan coverage); or
  - Medicare eligibility.

- For each surviving child, for the earlier of 36 months or
  - the end of the month in which the child turns age 26; or
  - the date of the child’s adoption by anyone other than the surviving spouse.

If the deceased participant’s MCTWF’s Actives Plan participating group’s medical and prescription drug benefits are suspended or terminated for any reason, the Survivor Health Benefits also will be suspended or terminated. MCTWF will require periodic status statements to ensure that each Survivor remains eligible.

Continuation of Coverage Beyond Age 26 for Disabled Dependent – Winter 2017-2018

A covered dependent is a MCTWF Actives Plan participant's natural or step child or a child who has been placed with a participant for adoption, or who has been adopted, and is eligible for MCTWF Actives Plan benefits. Dependent eligibility ceases at the end of the child’s 26th birthday month, except if the child is unmarried and, prior to age 26, was determined by a physician, psychologist or psychiatrist to be totally and permanently disabled. Total and permanent disability means that the person has a physical or mental condition that is expected to continue for the remainder of his life and that causes him to be unable to engage in any regular employment or occupation for compensation, profit or gain for which he may be suited in regard to education, training, or experience. If the disabled child is age 26 or greater and the total and permanent disability began before the child was covered under the MCTWF Actives Plan, the child’s eligibility as a covered dependent is contingent upon documentation evidencing that he was covered as the participant’s dependent under the participant’s health plan on the day immediately preceding participant’s establishment of eligibility under the MCTWF Actives Plan.

To continue coverage, a Request for Continuation of Coverage beyond Age 26 for Totally & Permanently Disabled Dependent form must be fully filled out and sent to MCTWF along with medical records supporting the dependent’s total and permanent disability. This form is available on the Forms page of MCTWF’s website at www.mctwf.org or by contacting MCTWF’s Member Services Call Center.

ELIGIBILITY – MCTWF RETIREES PLAN

Eligibility for MCTWF Retirees Plan – Post CBA Expiration – Fall 2015

The rule has been that the right of a retiring employee to enroll in the MCTWF Retirees Plan is suspended upon the expiration of his Collective Bargaining Agreement (CBA) and will remain so unless the parties agree to renew participation in MCTWF.

Effective October 1, 2015 this rule has been amended to permit an otherwise eligible affected retiree to enroll during the above described period if he is at least age 57 and has at least 30 years of participation in MCTWF.

Untimely Reporting of Employee Status Changes – Spring 2016

The Fund requires that all contributing employers timely report all active employment status changes (i.e., layoffs, terminations, resignations, personal leaves, military leaves, work related and non-work related illnesses and injuries, and other changes in status) so that the Fund can update its benefit eligibility records. The employer’s failure to do so may result erroneously in the provision of ongoing benefits for members who no longer are eligible. If you are no longer eligible, please inform your healthcare providers, including your pharmacist, that you no longer are covered for Fund benefits. Pharmacists, in particular, will assume that you are still covered by the Fund unless you inform them otherwise. The Fund will be obliged to pursue you to recover the cost of benefits erroneously provided to you.
MCTWF Retirees Plan Health Benefit Rates: – Spring 2016

The standard and expanded monthly self-contribution rates listed below apply to all those participating in the Fund’s basic Retirees Health Benefit Package 145, which have not increased from last year’s rates. For those purchasing Retirees Health Benefit Package 475 (which includes the Retiree Supplemental Benefits Rider - hearing, vision, and Dental Plan 2 benefits), add $100.75 (a decrease from last year’s rate) to Retirees Health Benefit Package 145 monthly rates:

<table>
<thead>
<tr>
<th>Age at MCTWF Retirement Date</th>
<th>Years Participating under an MCTWF Actives Plan Benefit Package with Retiree Health Component</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 – 9</td>
</tr>
<tr>
<td>50 – 54</td>
<td>$785</td>
</tr>
<tr>
<td>55 – 59</td>
<td>$605</td>
</tr>
<tr>
<td>60 – 64</td>
<td>$435</td>
</tr>
</tbody>
</table>

For eligible retirees whose active employment ceased prior to January 1, 2002: $365

To drop the Retiree Supplemental Benefits Rider you must have been covered by it for a minimum of 12 months and you must notify the Fund in writing at least 45 days prior to the end of the last calendar month for which you wish to be covered. For example, to drop coverage as of January 1st, the Fund must receive written notification by November 15th. Once the Retiree Supplemental Benefits Rider is dropped, it will not be available to you again.

<table>
<thead>
<tr>
<th>Age at MCTWF Retirement Date</th>
<th>Years Participating under an MCTWF Actives Plan Benefit Package with Retiree Health Component</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7 – 9</td>
</tr>
<tr>
<td>57 – 59</td>
<td>$665</td>
</tr>
<tr>
<td>60 – 64</td>
<td>$480</td>
</tr>
</tbody>
</table>

To drop the Retiree Supplemental Benefits Rider you must have been covered by it for a minimum of 12 months and you must notify the Fund in writing at least 45 days prior to the end of the last calendar month for which you wish to be covered. For example, to drop coverage as of January 1st, the Fund must receive written notification by November 15th. Once the Retiree Supplemental Benefits Rider is dropped, it will not be available to you again.

* Eligibility to participate in a Retiree Health Benefit Package (i.e., 145 or 475) ceases for the retiree or the spouse when he or she becomes eligible for Medicare Part A coverage or engages in prohibited employment (as defined by the Summary Plan Description Booklet). In the event that the retiree becomes eligible for Medicare Part A, the spouse may continue to participate in the Retiree Health Benefit Package at the retiree self-contribution rate until or unless such participation, from the date of commencement, exceeds eight years. Spouse participation then requires self-contribution at the Retiree Health Benefit Package’s cost based rates. If the retiree dies or becomes eligible for early age (disability) Medicare coverage, the otherwise eligible spouse may continue to participate in the Retiree Health Benefit Package at the retiree’s self-contribution rate, unless or until the later of (a) eight years from the date that the retiree’s health benefit package coverage began or (b) until the date the retiree would have attained age 65, after which, for so long as she remains eligible, the spouse may continue to participate at the Retiree Health Benefit Package’s cost based rate as an “Extended Retiree Spouse.”

Increase in MCTWF Retirees Plan Calendar Year Benefit: – Spring 2016

The MCTWF Retirees Plan health (medical and prescription drug) benefits calendar annual benefit limit, exclusive of Phase III Specified Organ Transplants, per covered individual, has been increased from $220,000 to $250,000, effective April 1, 2016.
MCTWF Retirees Plan Health Benefit Rates: – Spring 2017

The standard and expanded monthly self-contribution rates listed below apply to all those participating in MCTWF’s basic Retirees Health Benefit Package 145. These rates are unchanged from last year’s rates. For those purchasing Retirees Health Benefit Package 475 (which includes the Retiree Supplemental Benefits Rider - hearing, vision, and Dental Plan 2 benefits), add $100.75 (also unchanged from last year’s rate) to Retirees Health Benefit Package 145 monthly rates. All currently active Retirees have been notified of these self-contribution rates by separate mail.

<table>
<thead>
<tr>
<th>April 2017</th>
<th>Retiree Health Benefit Package 145 Standard Eligibility Rules Monthly Self-Contribution Rates (Covers Both the Retiree and the Eligible Spouse)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at MCTWF Retirement Date</td>
<td>Years Participating under an MCTWF Actives Plan Benefit Package with Retiree Health Component</td>
</tr>
<tr>
<td>60 – 64</td>
<td>5 – 9</td>
</tr>
</tbody>
</table>

To drop the Retiree Supplemental Benefits Rider you must have been covered by it for a minimum of 12 months and you must notify the Fund in writing at least 45 days prior to the end of the last calendar month for which you wish to be covered. For example, to drop coverage as of January 1st, the Fund must receive written notification by November 15th. Once the Retiree Supplemental Benefits Rider is dropped, it will not be available to you again.  

* Eligibility to participate in a Retiree Health Benefit Package (i.e., 145 or 475) ceases for the retiree or the spouse when he or she becomes eligible for Medicare Part A coverage or engages in prohibited employment (as defined by the Summary Plan Description Booklet). In the event that the retiree becomes eligible for Medicare Part A, the spouse may continue to participate in the Retiree Health Benefit Package at the retiree self-contribution rate until or unless such participation, from the date of commencement, exceeds eight years. Spouse participation then requires self-contribution at the Retiree Health Benefit Package’s cost based rates (which also remain unchanged from last year). If the retiree dies or becomes eligible for early or disability Medicare coverage, the otherwise eligible spouse may continue to participate in the Retiree Health Benefit Package at the retiree’s self-contribution rate, unless or until the later of (a) eight years from the date that the retiree’s health benefit package coverage began or (b) until the date the retiree would have attained age 65, after which, for so long as she remains eligible, the spouse may continue to participate at the Retiree Health Benefit Package’s cost based rate as an “Extended Retiree Spouse.”

MCTWF Retirees Medical Benefit Package Rates for Plan Year: April 2018 – March 2019: – Spring 2017

Effective April 2018, the standard and expanded monthly self-contribution rates listed below apply to all those participating in the MCTWF Retirees Plan basic medical Benefit Package 145. For those purchasing Benefit Package 475 (which includes the Retiree Supplemental Benefits Rider - Hearing, Vision, and Dental Plan 2 benefits), add $100.10 to Benefit Package 145 monthly rates.

Please note: To drop the Retiree Supplemental Benefits Rider included in Benefit Package 475, you must have been covered by it for a minimum of 12 months and you must notify MCTWF in writing at least 45 days prior to the end of the last calendar month for which you wish to be covered. For example, to drop coverage as of January 1st, MCTWF must receive written notification by November 15th. Once the Retiree Supplemental Benefits Rider is dropped, it will not be available to you again.

<table>
<thead>
<tr>
<th>April 2018</th>
<th>Retiree Medical Benefit Package 145 Standard Eligibility Monthly Self- Contribution Rates (Covers Both the Retiree and the Eligible Spouse)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at MCTWF Retirement Date</td>
<td>Years Participating in MCTWF under an Active Benefit Package with Retiree Medical Component</td>
</tr>
</tbody>
</table>

For eligible retirees whose active employment ceased prior to January 1, 2002: $330
### April 2018

<table>
<thead>
<tr>
<th>Age at MCTWF Retirement Date</th>
<th>Years Participating in MCTWF under an Active Benefit Package with Retiree Medical Component</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7 – 9</td>
</tr>
<tr>
<td>57 – 59</td>
<td>$600</td>
</tr>
<tr>
<td>60 – 64</td>
<td>$430</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age at Start of Each Plan Year</th>
<th>5 – 9</th>
<th>10 – 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 – 52</td>
<td>$526.70</td>
<td>$428.80</td>
</tr>
<tr>
<td>53 – 55</td>
<td>$574.70</td>
<td>$543.20</td>
</tr>
<tr>
<td>56 – 58</td>
<td>$596.50</td>
<td>$664.75</td>
</tr>
<tr>
<td>59 – 61</td>
<td>$617.65</td>
<td>$781.60</td>
</tr>
<tr>
<td>62 – 64</td>
<td>$652.75</td>
<td>$870.00</td>
</tr>
</tbody>
</table>

* Eligibility to participate in the MCTWF Retirees Plan (Benefit Package 145 or 475) ceases for the retiree or the spouse when he or she becomes eligible for Medicare Part A coverage or engages in prohibited employment (as defined by the Summary Plan Description Booklet). In the event that the retiree becomes eligible for Medicare Part A, the spouse may continue to participate at the retiree self-contribution rate that would have been applicable to the retiree until or unless non-deferred participation (i.e., eligibility for coverage) in the MCTWF Retirees Plan exceeds eight years. Spouse participation then requires self-contribution at the Extended Retiree Spouse rates for the applicable benefit package. If the retiree dies or becomes eligible for early age (disability) Medicare coverage, the otherwise eligible spouse may continue to participate at the retiree’s self-contribution rate that would have been applicable to the retiree, unless or until the later of (a) eight years of non-deferred participation, or (b) until the date the retiree would have attained age 65, after which, for so long as she remains eligible, the spouse may continue to participate at the Extended Retiree Spouse rates for the applicable benefit package.

### ELIGIBILITY – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

#### Same Sex Marriage Eligibility – Termination of Domestic Partner Eligibility – Fall 2015

In light of the Supreme Court’s June 25, 2015 ruling, MCTWF now recognizes as an eligible beneficiary a participant’s same sex spouse. In order to effectuate coverage, as with all new spouses, participants must identify their spouse through the submission of an updated MCTWF Enrollment Card or a Change in Family Status, provide a copy of their marriage certificate, and otherwise comply with MCTWF’s spouse eligibility rules.

Now that MCTWF recognizes same sex marriages, those partners who were approved for eligibility under MCTWF’s Domestic Partner Eligibility rules and presently participate in MCTWF under those rules will lose MCTWF eligibility effective January 1, 2016.

#### COBRA Continuation Coverage - Contribution Tiers – Spring 2017

COBRA continuation coverage contribution rates are based on two coverage tiers, “single” and, for two or more people, “family.” To date, once paying the family contribution rate, you remain obligated to continue to do so, even when your coverage is reduced to just one person.

Effective May 4, 2017, if during the period of COBRA continuation coverage, coverage for your family unit is reduced to just one person due to death, eligibility for Medicare, or exhaustion of COBRA eligibility periods, your contribution rate will be reduced to the required amount for single tier coverage.
MEDICAL BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Home Cervical Traction Devices – New Benefit – Fall 2015
Cervical Traction can be performed safely at home in lieu of receiving such treatment at a physical therapist’s office. Effective August 6, 2015, MCTWF covers the purchase of a physician prescribed Home Cervical Traction Device as a Durable Medical Equipment benefit, subject to prior authorization for medical necessity by MCTWF’s Utilization Review Department, based on the following criteria –
- For over-the door cervical traction devices -
  - The patient must have a musculoskeletal or neurologic impairment requiring traction equipment; and
  - The appropriate use of a home cervical traction device must have been professionally demonstrated to the patient and the patient tolerated the device.
- For Pneumatic cervical traction devices applying traction force to other than the mandible, and cervical traction equipment not requiring an additional stand or frame -
  - The member must have a musculoskeletal or neurologic impairment requiring traction equipment;
  - The appropriate use of a home cervical traction device must have been demonstrated to the patient and the patient tolerated the device; and
  - Any of the following criteria is met:
    ✓ The treating physician orders and documents the medical necessity of 20 pounds or more of home cervical traction; or
    ✓ The member has temporomandibular joint (TMJ) dysfunction and has received treatment for the TMJ condition; or
    ✓ The member has distortion of the lower jaw or neck anatomy (e.g., radical neck dissection) such that a chin halter is unable to be utilized.

Non-Surgical Spinal Decompression Therapy – Fall 2015
Effective with service dates of January 1, 2016 and after, non-surgical spinal decompression therapy no longer is a MCTWF covered benefit.

ABA Coverage for Autism Spectrum Disorders – Benefit Limits Removed – Fall 2015
Effective with service dates of January 1, 2016 and after, all limits on MCTWF Applied Behavior Analysis (ABA) coverage for autism spectrum disorders are eliminated.

Specialty Medical Carve-Out Program – Fall 2015
Effective January 1, 2016, MCTWF will implement in limited form CVS/caremark’s Specialty Medical Carve-Out Program (Program). Under the Program, oral and injectable specialty medications, other than those for cancer treatment, which are provided and/or administered by a physician will be “carved-out” of the MCTWF medical benefit and covered under the MCTWF pharmacy benefit. The specialty medication will be available to the provider or patient through the CVS/caremark specialty pharmacy. In addition to benefiting MCTWF with CVS/caremark’s substantial discounts, the “Program” will manage utilization through prior authorization, step therapy, dose/waste claim management, and education.

Consilium – Medical Bill Negotiation – Fall 2015
In June, all participants and spouses covered by a MCTWF medical benefits package received new MCTWF Networks Cards. While we urge you to use a Blue Cross Blue Shield participating provider whenever possible to avoid your exposure to balance billing for amounts in excess of MCTWF maximum allowable benefits, as we stated in the notice that accompanied the Cards, effective July 1, 2015 all medical claims for services rendered by non-Blue Cross Blue Shield participating providers are referred by MCTWF to Consilium, an expert bill negotiation vendor, with the goal of eliminating patient balance billing by the provider through Consilium’s negotiation of a settlement with it. If Consilium is unsuccessful, it determines whether the provider belongs to one or more of 150 provider networks and therefore subject to contractual limits on its charges. If either approach is successful, the patient’s financial responsibility only will be for the payment of his required deductible and or coinsurance charge. However, since Consilium’s negotiation is likely to result in lower payment to the provider (and therefore a lower coinsurance charge to you) than would a network contractually based amount, and since Consilium cannot negotiate a bill that you have already paid, we urge you to resist the provider’s request that you pay the bill when the services are provided.
Inform the provider that your benefit plan provides coverage even though the provider does not participate with Blue Cross Blue Shield and that it should submit a claim for payment to the local Blue Cross Blue Shield participating plan and bill you later if there is an amount still owed. For the first three months of MCTWF’s use of Consilium, MCTWF members have avoided patient balance billing totaling almost $400,000.

Developmental Speech Therapy – New Benefit – Fall 2015
MCTWF benefits cover unlimited therapy designed to restore and maintain speech function (restorative speech therapy). Effective November 5, 2015 MCTWF benefits include coverage designed to develop and maintain a child’s speech function (developmental speech therapy) when the services provided by the child’s school district are deemed by the Fund to be inadequate to meet the child’s reasonable needs.

In order to be eligible for developmental speech therapy, such services must be prior authorized annually by MCTWF’s Utilization Review Department, subject to review of the child’s current Individualized Education Plan (IEP) and a letter of medical necessity from the referring physician must be provided to the Fund.

Approved developmental speech therapy is paid in accordance with the provider’s participating status with BCBS PPO and the patient’s medical benefit package, subject to the same coinsurance rate as the restorative speech therapy benefit, a maximum of 30 visits each calendar year, and only until the last day of the month in which the child turns 18 years old.

Dentist and Dental surgeon Services Covered under Medical Services - Clarification – Fall 2015
MCTWF medical benefits cover services secondary to dental coverage for repair of natural teeth as the direct result of an accidental injury or caused by congenital or genetic abnormalities. Charges first are applied against available dental benefit limits before being covered under the member’s medical benefits.

Coverage for Medically Necessary, Non-Implantable Contact Lenses – Fall 2016
Certain eye conditions cannot be addressed adequately through surgical correction or the use of eyeglasses and require, as medically necessary, the use of special, non-implantable contact lenses. Effective September 28, 2016, the following diagnoses are covered as a medical service when submitted with an appropriate vision procedure code:

- Keratoconus
- Aphakia
- Anisometropia
- Aniseikonia
- Dry Eye Syndrome or Bilateral Lacrimal Glands
- Presence of Intraocular Lens
- Cataract Extraction Status

Medically necessary, non-implantable contact lenses are payable as durable medical equipment and the applicable deductible and/or coinsurance will apply in accordance with your benefit package.

Prior Authorization for Advanced Imaging Requests and In-Lab Sleep Studies – Fall 2016
MCTWF has utilized the Blue Cross Blue Shield of Michigan (BCBSM) Clinical Review Management Program (“Program”) administered by American Imaging Management (AIM) for BCBSM participating providers to obtain prior authorization for outpatient non-emergency “advanced imaging” diagnostic services (i.e., CT scans, MRIs, PET scans, nuclear medicine, and echocardiography) and for all in-lab sleep studies. Prior to November 1, 2016, Michigan providers who did not participate in the Blue Cross Blue Shield networks and all providers outside of Michigan were required to seek prior authorization for advanced imaging and in-lab sleep studies from MCTWF’s Utilization Review Department.

Effective with dates of services November 1, 2016 and after, non-Michigan providers who participate in the Blue Cross Blue Shield networks are required to comply with the Program by seeking prior authorization for outpatient non-emergency advanced imaging diagnostic services from AIM at 800-728-8008. All providers who do not participate in the Blue Cross Blue Shield networks must continue to seek prior authorization for outpatient non-emergency advanced imaging diagnostic services from MCTWF’s Utilization Review Department and all providers outside of Michigan must continue to seek prior authorization for in-lab sleep studies from MCTWF’s Utilization Review Department. Please be aware that if prior authorization is not granted, you will be responsible for the cost of the service.

Those affected by this change will receive new, gold colored BCBSM ID cards with the advanced imaging diagnostic services and in-lab sleep studies phone numbers included on the back. Please begin presenting this card immediately for all medical services and destroy your current BCBSM ID card (but retain your white colored MCTWF Networks card; that card remains in effect).
Effective with dates of services 09/01/16 and after, the Fund has adopted Blue Cross Blue Shield of Michigan’s medical policy guidelines for medically necessary transgender services to provide gender reassignment surgery, hormone therapy, doctor’s office and lab testing, and counseling for participants and beneficiaries with gender dysphoria. Investigational transgender services continue not to be covered.

The established treatments of gender dysphoria include:
- Puberty suppression in adolescents
- Cross-sexual hormone therapy (for masculinization/feminization)
- Medically necessary gender reassignment surgery, which requires prior authorization:
  - Genitalia reconstruction
  - Mastectomy in female-to-male transitions

Gender specific services may be medically necessary for transgender persons appropriate to their anatomy. Examples include:
- Breast cancer screening may be medically necessary for female-to-male transitioned persons who have not undergone a mastectomy.
- Prostate cancer screening may be medically necessary for male-to-female transitioned persons who have retained their prostate.
- Cervical screening may be medically necessary for female-to-male transitioned persons, as needed.

Puberty Suppression

Puberty suppression hormones for adolescents (note: these are covered under the participant’s pharmacy benefit) may be indicated for participants and beneficiaries that meet all of the following inclusionary criteria:
- Onset of puberty to at least Tanner stage 2;
- The adolescent dependent child has demonstrated a long-lasting and intense pattern of gender nonconformity of gender dysphoria (whether suppressed or expressed);
- Gender dysphoria emerged or worsened with the onset of puberty;
- Any coexisting psychological, medical or social problems that could interfere with treatment (e.g., that may compromise treatment adherence) have been addressed, such that the adolescent dependent child’s situation and functioning are stable enough to start treatment;
- The adolescent dependent child has given informed consent and, particularly when the adolescent dependent child has not reached the age of medical consent, the participant and/or spouse or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent dependent child throughout the treatment process; and
- The absence of contraindications to therapy in the judgment of the managing physician.

Hormone Therapy

Hormone therapy (note: covered under the participant’s pharmacy benefit) may be indicated for participants and beneficiaries that meet all of the following inclusionary criteria:
- Persistent, well-documented gender dysphoria;
- Capacity to make a fully informed decision and to consent for treatments;
- 18 years of age or older (age of majority);
- If significant medical or mental health concerns are present, they must be reasonably well-controlled; and
- The absence of contraindications to therapy in the judgment of the managing physician.

Gender Reassignment Surgery

Gender reassignment surgery may be indicated for participants and beneficiaries that meet all of the following inclusionary criteria:
- Persistent, well-documented gender dysphoria;
- The provider must supply documentation that supports the participant or beneficiary meets criteria for gender assignment surgery;
Michigan Conference of Teamsters Welfare Fund

- This includes a detailed psychological assessment by either a psychiatrist, PhD prepared clinical psychologist or a master’s prepared social worker (MSW) under the supervision of a psychiatrist or PhD prepared clinical psychologist
- 18 years of age or older;
- Capacity to make a fully informed decision and to consent to treatment;
- If significant medical or mental health concerns are present, they must be controlled; and
- 12 continuous months of hormone therapy* as appropriate to the patient’s gender role (unless there is a contraindication to hormonal therapy):
  - *Hormonal therapy is not required prior to mastectomy in female-to-male patients.
  - The aim of hormone therapy prior to a gonadectomy is primarily to introduce a period of reversible estrogen or testosterone suppression, before the patient undergoes irreversible surgical intervention.

Some patients receiving transgender services may require and benefit from ongoing behavioral health services, including psychotherapy.

Exclusions

The following services are excluded under the medically necessary transgender benefit:

- Reversal of transgender surgical procedures.
- All surgical procedures that are primarily cosmetic and not medically necessary including but not limited to:
  - Abdominoplasty
  - Blepharoplasty
  - Breast enhancements
  - Brow lift
  - Calf implants
  - Cheek/malar implants
  - Chin/nose implants
  - Chondrolaryngoplasty (Adam’s apple reduction)
  - Collagen injections
  - Construction of a clitoral hood
  - Drugs for hair loss or growth
  - Forehead lift
  - Hair removal
  - Hair transplantation
  - Lip reduction
  - Liposuction
  - Mastopexy
  - Neck tightening
  - Pectoral implants
  - Removal of redundant skin
  - Rhinoplasty
  - Speech-language therapy
  - Non-covered services

FluMist® Not Covered this Flu Season – Fall 2016

The American Academy of Pediatrics and the Centers for Disease Control and Prevention warn that FluMist® (a live attenuated influenza vaccine administered by intranasal spray) generally has proven ineffective in protecting against influenza strains that were most prominent during the past three flu seasons, especially in children (for whom the nasal spray vaccine was developed), and recommend that children ages 6 months and older receive a seasonal flu shot as the best available protection against influenza. Accordingly, and consistent with Blue Cross Blue Shield of Michigan medical policy, MCTWF will not cover FluMist® nasal spray vaccine for the 2016-2017 flu season.

Colonoscopy Screenings – Spring 2017

MCTWF’s preventive/wellness benefits include no-cost coverage of colonoscopy screenings if the patient’s history reveals no risk factors for colorectal cancer other than being age 50 or greater, or if African-American, age 45 or greater. If the screening results are normal and of reasonable quality, a preventive/wellness follow-up colonoscopy is covered once every five years thereafter.
If a preventive/wellness colonoscopy screening fails due to improper or incomplete preparation by the patient, the failed screening will be covered at no cost to the patient, but **effective May 4, 2017**, the follow-up screening will be treated as a medical benefit subject to the cost sharing requirements of the patient’s MCTWF benefit package.

**MDLIVE Telehealth Services – Extension of $0 Copay Through March 31, 2018 – Spring 2017**

Three years ago, MCTWF introduced a convenient service for treatment of many non-acute medical conditions through the use of telehealth consultations provided by MDLIVE. MDLIVE provides on-demand access to U.S. Board certified physician and licensed behavioral health therapist consultations. Medical consultations are available 24 hours, 7 days a week, by phone or secure video. Behavioral health consultations are available 8 am to 11 pm Eastern time, Monday through Friday, by secure video only. Members who have used MDLIVE services and have agreed to be surveyed consistently have acknowledged its convenience and ease and their satisfaction with the consultation. MCTWF’s Trustees have extended the $0 copay policy for another year, through March 31, 2018.

**Register with MDLIVE for a Chance to Win a Prize! – Spring 2017**

MDLIVE once again will be conducting a drawing to choose two members, each of whom will win a $100 dollar VISA gift card and an MDLIVE sport water bottle. To be eligible to win, a member must be a MCTWF participant, spouse, or adult child, covered for medical benefits at the time of the drawing, and must have registered with MDLIVE between June 19, 2017 and July 31, 2017. If previously registered, the member must request to be part of the drawing. Registration is easy and it will speed up the time it will take to arrange for your first consultation when you need it. You can register on-line at www.mdlive.com/mctwf, or via the Info Links page of the MCTWF’s website, or by phone, with the help of an MDLIVE health services specialist at 888-632-2738. If you previously registered, you will need to send an email by July 31, 2017 to promotions@mdlive.com and include on the subject line - “MCTWF Promotion Certification.” In the body, state your full name and that you would like to participate in the MDLIVE/MCTWF drawing. Good luck!

**Reconstructive Surgery to Remove Excess Skin – Spring 2017**

Surgical procedures, treatment, or hospitalization primarily for reconstructive purposes generally are deemed covered services if the procedure is primarily intended to improve/restore bodily function or to correct significant deformity resulting from accidental injury, trauma, or previous therapeutic process, or if the procedure is intended to correct congenital or developmental anomalies that have resulted in significant functional impairment. Such covered services include the removal of excess skin when deemed by MCTWF to be medically necessary, resulting from massive weight loss, except when due to bariatric surgery.

Effective with dates of service February 2, 2017 and after, subject to prior authorization, **MCTWF benefits have been expanded to cover the removal of excess skin in the case of massive weight loss due to bariatric surgery causing functional impairment**, including but not limited to, severe rashes or intertrigo (skin inflammation usually in warm, moist areas between skin folds) skin ulceration, pain, etc., that has not responded to conventional medical therapy (e.g., topical antifungals, topical and/or systemic corticosteroids, and/or local or systemic antibiotics).

**Medical Bill Negotiation – Spring 2017**

Since July 1, 2015, all unpaid medical claims for services rendered by non-Blue Cross Blue Shield providers have been referred by MCTWF to Consilium, an expert medical bill negotiation vendor, with the goal of settling the bill at MCTWF’s expense to protect the patient from provider balance billing (i.e., the difference between the amount billed and MCTWF’s maximum allowable benefit). If successful, the patient’s financial responsibility is limited to the payment of any required deductible and coinsurance charge. Through March 31, 2017, patients have avoided about $2 million in balance billing because of this program.

However, effective with August 1, 2017 dates of services, non-Blue Cross Blue Shield lab service providers, ordered by your healthcare provider (other than when you are in a hospital inpatient setting) will not be negotiated by Consilium. It is the patient’s responsibility to make sure that lab services used by the physician are being rendered by a Blue Cross Blue Shield participating provider. The non-Blue Cross Blue Shield provider lab claim will be reimbursed to the participant based on MCTWF’s maximum allowable benefit amount and subject to out-of-network cost sharing benefit levels.

Please remember always to obtain medical services from a Blue Cross Blue Shield provider, but if you cannot do so, keep in mind that Consilium cannot negotiate a bill that you have already paid. We urge you to resist the non-Blue Cross Blue Shield provider’s demand for full payment when services are provided. Assert that your benefit plan provides coverage for out-of-network services and so the provider should submit a claim for payment to the local Blue Cross Blue Shield participating plan and bill you later if there is an amount still owed.

The Women’s Health and Cancer Rights Act (Women’s Health Act) was signed into law October 21, 1998. This law amended the Employee Retirement Income Security Act of 1974 (ERISA) and provides important protections for breast cancer patients who elect breast reconstruction in connection with a mastectomy. Under the Women’s Health Act, group health plans offering mastectomy coverage (such as MCTWF) must also provide for reconstructive surgery in a manner determined in consultation between the attending physician and the patient. Coverage must include:

- reconstruction of the breast on which the mastectomy was performed;
- Surgery and reconstruction of the other breast to produce a symmetrical appearance; and
- prostheses and treatment of physical complications at all stages of the mastectomy, including lymphedema.

Medical Coverage for Dental Services – Winter 2017-2018

MCTWF provides medical coverage (at out-of-network benefit levels) for dental services rendered to repair accidental injuries (other than those that are work-related or auto-related injuries) to natural teeth, as well as coverage for the correction of congenital and genetic dental abnormalities.

Effective 5/4/17, coverage has been expanded to include the repair of natural teeth when catastrophic compromise of natural teeth occurs as the result of disease, or treatment of a disease.

Payment of allowed charges first will be applied against available dental limits before being covered as a medical benefit.

MCTWF Requests for Medical Records – Winter 2017-2018

On occasion, MCTWF requires the review of medical records to determine your benefit entitlement. All requests for medical records are directed to the patient and a copy of the request is sent to the patient’s service provider. Please be aware, however, that if the service provider requires a fee to produce your medical records, MCTWF is not responsible for reimbursing you or paying the provider directly. Medical records include, but are not limited to, hospital records, emergency room reports, ambulance run reports, and office notes from your physician or other medical professional.

Coverage for Ambulance Services Who No Transport Occurs – Winter 2017-2018

For those who are covered under a medical benefits package, eligible expenses are payable for licensed ground, air, or water ambulance services for basic and advanced life support for treatment of a medical emergency. Eligible expenses include transportation to a medical facility, or other treatment location, when transport by any other means would endanger the patient’s health, or when the injury requires immediate first aid to stabilize the patient before transport.

Ambulance services are payable without transport in the following situations:

- The ambulance arrives at the scene, the patient is stabilized, and transport either is not needed or is refused.
- The ambulance arrives at the scene but the patient has expired.

Digital Breast Tomosynthesis (3D Mammography) Coverage – Winter 2017-2018

Effective December 7, 2017, MCTWF’s annual mammography under the preventative/wellness screening service, where the applicable deductible and/or coinsurance is waived, has been expanded to include the 3D mammography screening service and can be covered in lieu of the standard annual mammography, based on the physician orders and provided that the service is billed as a screening, subject to your benefit package applicable deductible and/or coinsurance amounts. Otherwise, the service will be covered under the medical benefit and the applicable deductible and/or coinsurance will apply.

Private Duty Nursing – Winter 2017-2018

MCTWF pays for private duty nursing in the patient’s home by a registered nurse or licensed practical nurse, for so long as the service is medically necessary and has received prior authorization by MCTWF, subject to renewal authorizations every 30 days after the initial approval.

Private duty nursing is provided to individuals who need skilled care and whose condition requires individual and continuous 24-hour nursing care that is more intense than what is available under MCTWF’s home health care benefit. The purpose of private duty nursing is to assist the patient with medical care and to train caregivers to provide such medical care in the nurse’s absence, enabling the patient to remain in his home.
Michigan Conference of Teamsters Welfare Fund

Effective December 7, 2017 the lifetime maximums for private duty nursing have been removed. Private duty nursing that is deemed medically necessary is covered for up to 16 hours of care per day for the transition period from inpatient hospital to home care. Following the transition period, up to 10 hours of care per day will be covered for as long as medical necessity continues.

Maternity Benefit – Ultrasound Limit – Winter 2017-2018

MCTWF’s maternity benefits cover pre-natal care, post-natal care and obstetrical services. Benefits for pre-natal care include up to three ultrasound imaging services per pregnancy. Coverage of any additional ultrasound claims is contingent upon a determination by MCTWF of medical necessity.

PRESCRIPTION DRUG BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Notice of Creditable Coverage All MCTWF Benefit Packages with Prescription Drug Coverage – Fall 2015

The following Notice is published in accordance with regulations promulgated by the Centers for Medicare and Medicaid Services, pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003:

---

**Important Notice from the Michigan Conference of Teamsters Welfare Fund (MCTWF) About Your Prescription Drug Coverage and Medicare**

Please read this notice carefully and keep it where you can find it. This notice has information about your current prescription drug coverage with MCTWF and about your options under Medicare’s prescription drug coverage. This information can help you decide whether or not you want to join a Medicare drug plan. If you are considering joining, you should compare your current coverage, including which drugs are covered at what cost, with the coverage and costs of the plans offering Medicare prescription drug coverage in your area. Information about where you can get help to make decisions about your prescription drug coverage is at the end of this notice. There are two important things you need to know about your current coverage and Medicare’s prescription drug coverage:

1. Medicare prescription drug coverage became available in 2006 to everyone with Medicare. You can get this coverage if you join a Medicare Prescription Drug Plan or join a Medicare Advantage Plan (like an HMO or PPO) that offers prescription drug coverage. All Medicare drug plans provide at least a standard level of coverage set by Medicare. Some plans may also offer more coverage for a higher monthly premium.

2. MCTWF has determined that the prescription drug coverage offered by all MCTWF benefit packages with prescription drug coverage, on average for all plan members, is expected to pay out as much as standard Medicare prescription drug coverage pays and therefore is considered Creditable Coverage. Because your existing coverage is Creditable Coverage, you can keep this coverage and not pay a higher premium (a penalty) if you later decide to join a Medicare drug plan.

---

**When can you join a Medicare drug plan?**

You can join a Medicare drug plan when you first become eligible for Medicare and each year from October 15th through December 7th. However, if you lose your current creditable prescription drug coverage, through no fault of your own, you will also be eligible for a two (2) month Special Enrollment Period (SEP) to join a Medicare drug plan.

**What happens to your current coverage if you decide to join a Medicare Drug Plan?**

If you decide to join a Medicare drug plan, under MCTWF rules you nonetheless may not drop your MCTWF prescription drug coverage. If you have both MCTWF prescription drug coverage and Medicare prescription drug coverage, MCTWF prescription drug coverage will be primary and your Medicare prescription drug plan will be secondary. If you are a COBRA beneficiary you may drop your MCTWF coverage in full, including prescription drug coverage, and enroll in a Medicare prescription drug plan. However, you will not be able to get your MCTWF COBRA coverage back later. If you do elect COBRA continuation coverage, your COBRA prescription drug coverage will be secondary to your Medicare prescription drug plan coverage. You should compare your current coverage, including which drugs are covered, with the coverage and cost of the plans offering Medicare prescription drug coverage in your area. Your current prescription drug plan provides comprehensive coverage for eligible prescription drugs, subject to preauthorization requirements for certain brand name prescription drugs and for prescription drugs within the following drug classifications: compound drugs, non-sedating antihistamines (until 12/31/15, thereafter not covered), proton pump inhibitors (effective 1/1/16, after a 90 day generic supply during a 365 day period, or if a brand is requested), selective serotonin reuptake inhibitors (brand name only), anabolic steroids, anti-obesity, ADHD/narcolepsy (age 20 and above), acne, and oral anti-fungal drugs, subject to generic and brand copays, as detailed in your Summary Plan Description booklet. Your current coverage pays for other health expenses, in addition to prescription drugs, and you still will be eligible to receive all of your current health and prescription drug benefits if you choose to enroll in a Medicare prescription drug plan.

**When will you pay a higher premium (penalty) to join a Medicare Drug Plan?**

You should also know that if you drop or lose your current coverage with MCTWF and don’t join a Medicare drug plan within 63 continuous days after your current coverage ends, you may pay a higher premium (a penalty) to join a Medicare drug plan later. If
you go 63 continuous days or longer without creditable prescription drug coverage, your monthly premium may go up by at least 1% of the Medicare base beneficiary premium per month for every month that you did not have that coverage. For example, if you go nineteen months without creditable coverage, your premium may consistently be at least 19% higher than the Medicare base beneficiary premium. You may have to pay this higher premium (a penalty) as long as you have Medicare prescription drug coverage. In addition, you may have to wait until the following October to join.

For more information about this notice or your current prescription drug coverage…
Contact MCTWF’s Member Services Call Center at (313) 964-2400 or (800) 572-7687. NOTE: You’ll get this notice each year. You will also get it before the next period you can join a Medicare drug plan, and if this coverage through MCTWF changes. You also may request a copy of this notice at any time.

For more information about your options under Medicare prescription drug coverage…
More detailed information about Medicare plans that offer prescription drug coverage is in the “Medicare & You” handbook. You’ll get a copy of the handbook in the mail every year from Medicare. You may also be contacted directly by Medicare drug plans. For more information about Medicare prescription drug coverage:

- Visit www.medicare.gov
- Call your State Health Insurance Assistance Program (see the inside back cover of your copy of the “Medicare & You” handbook for their telephone number) for personalized help
- Call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048

If you have limited income and resources, extra help paying for Medicare prescription drug coverage is available. For information about this extra help visit Social Security on the web at www.socialsecurity.gov, or call them at 1-800-772-1213 TTY 1-800-325-0778).

Remember: Keep this Creditable Coverage notice. If you decide to join one of the Medicare drug plans, you may be required to provide a copy of this notice when you join to show whether or not you have maintained creditable coverage and, therefore, whether or not you are required to pay a higher premium (a penalty).

September 1, 2015
Michigan Conference of Teamsters Welfare Fund

Drugs Requiring Prior Authorization – Fall 2015
As was first announced in the winter 2011-2012 Messenger, MCTWF’s pharmacy benefit manager, CVS/caremark, made prior authorization of prescription drugs that are not on its Standard Formulary list, a condition of coverage. The following list reflects each such drug requiring prior authorization, its therapeutic class, the common medical condition that the class treats, and the alternative drugs in that therapeutic class (i.e., those not requiring prior authorization). Effective January 1, 2016, those drugs stated in bold are no longer formulary drugs and require prior authorization. CVS/caremark will so notify current utilizers of the newly added drugs and their prescribing physician and will provide them with a list of covered alternative drugs that are therapeutically equal in effectiveness. Please note that generic drugs are in lowercase italics font and brand drugs are in UPPERCASE roman font. To obtain prior authorization, your physician must contact CVS/caremark at 800-626-3046.

<table>
<thead>
<tr>
<th>Common Condition/Therapeutic Class</th>
<th>Drug Subject to Prior Authorization</th>
<th>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic Reaction (Anaphylaxis) Treatment</td>
<td>ADRENACLICK</td>
<td>AUVI-Q, EPIPEN, EPIPEN JR</td>
</tr>
<tr>
<td>Allergies Nasal Steroids/Combinations</td>
<td>BECONASE AQ, OMNARIS QNASL</td>
<td>flunisolide spray, fluticasone spray, triamcinolone spray, NASONEX</td>
</tr>
<tr>
<td></td>
<td>DYMISTA</td>
<td>flunisolide spray, fluticasone spray, triamcinolone spray, NASONEX WITH azelastine spray or PATANASE</td>
</tr>
<tr>
<td>Allergies Ophthalmic</td>
<td>LASTACAFT</td>
<td>azelastine, cromolyn sodium, PATADAY, PATANOL</td>
</tr>
<tr>
<td>Anti-infectives, Antivirals</td>
<td>VALCYTE</td>
<td>valganciclovir</td>
</tr>
<tr>
<td>Hepatitis C Agents</td>
<td>VIEKIRA PAK</td>
<td>HARVONI</td>
</tr>
<tr>
<td>Common Condition/Therapeutic Class</td>
<td>Drug Subject to Prior Authorization</td>
<td>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Anti-infectives, Antivirals</td>
<td>VALTREX</td>
<td>acyclovir, valacyclovir</td>
</tr>
<tr>
<td>Anti-infectives, Antivirals</td>
<td>QSYMIA</td>
<td>BELVIO, CONTRAVE, SAXENDA</td>
</tr>
<tr>
<td>Anti-infectives, Antivirals</td>
<td>PROVENTIL HFA</td>
<td>XOPENEX HFA</td>
</tr>
<tr>
<td>Asthma</td>
<td>PROAIR HFA,</td>
<td>ADVAIR, DULERA, ASMANEX, FLOVENT, PULMICORT FLEXHALER, QVAR</td>
</tr>
<tr>
<td>Asthma</td>
<td>AEROSPAN</td>
<td>ADVAIR, DULERA, ASMANEX, FLOVENT, PULMICORT FLEXHALER, QVAR</td>
</tr>
<tr>
<td>Asthma or Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>SYMPLICORT</td>
<td>ADVAIR, DULERA, ASMANEX, FLOVENT, PULMICORT FLEXHALER, QVAR</td>
</tr>
<tr>
<td>Depression</td>
<td>ADDERALL XR</td>
<td>amphetamine-dextroamphetamine mixed salts, amphetamine-dextroamphetamine mixed salts, ext-rel, guanfacine ext-rel, methylphenidate, methylphenidate ext-rel, DAYTRANA, QUILLVANT XR, STRATTERA, VYVANCE</td>
</tr>
<tr>
<td>Depression</td>
<td>TRICOR</td>
<td>fenofobrate, fenofibrin acid</td>
</tr>
<tr>
<td>Depression</td>
<td>ADVICOR</td>
<td>atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, CRESTOR, SIMCOR, VYTORIN</td>
</tr>
<tr>
<td>Depression</td>
<td>INCRUSE ELLIPTA</td>
<td>SPIRIVA</td>
</tr>
<tr>
<td>Depression, Schizophrenia</td>
<td>CYMBALTA</td>
<td>duloxetine, venlafaxine, venlafaxine ext-rel, KHEDEZLA, PRISTIQ</td>
</tr>
<tr>
<td>Depression, Schizophrenia</td>
<td>QLEPTRO</td>
<td>trazodone</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Fluorouracil cream 0.5% CARAC</td>
<td>fluorouracil cream 5%, fluorouracil soln, imiquimod, PICATO, ZYCLARA</td>
</tr>
<tr>
<td>Dermatology</td>
<td>NORITATE</td>
<td>metonidazole, sulfacetamide-sulfur, FINACEA, SOOLANTRA</td>
</tr>
<tr>
<td>Dermatology Skin Inflammation and Hives Corticosteroids</td>
<td>clobetasol spray // CLOBEX SPRAY OULX-E</td>
<td>clobetasol foam</td>
</tr>
<tr>
<td>Diabetes Biguanides</td>
<td>FORTAMET</td>
<td>metformin, metformin ext-rel</td>
</tr>
<tr>
<td>Diabetes Biguanides</td>
<td>OSENI</td>
<td>JANUMET, JANUMET XR, JENTADUETO</td>
</tr>
<tr>
<td>Diabetes InsulinSensitizers</td>
<td>ACTOS</td>
<td>pioglitazone</td>
</tr>
<tr>
<td>Diabetes Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Combinations</td>
<td>KAZANO KOMBIGLYZE XR</td>
<td>JANUMET, JANUMET XR, JENTADUETO</td>
</tr>
<tr>
<td>Diabetes Injectable Incretin Mimetics</td>
<td>BYDUREON BYETTA</td>
<td>TRULICITY, VICTOZA</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>APIRA</td>
<td>NOVOLOG</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMANLOF</td>
<td>NOVOLOG MIX 70/30</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMANLOG MIX 50/50</td>
<td>NOVOLOG MIX 70/30</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMANLOG MIX 75/25</td>
<td>NOVOLOG MIX 70/30</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMULIN 70/30</td>
<td>NOVOLIN 70/30</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMULIN N</td>
<td>NOVOLIN N</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>HUMULIN R</td>
<td>NOVOLIN R</td>
</tr>
<tr>
<td>Diabetes Insulins</td>
<td>NOTE: Humulin R U-500 concentrate will not be subject to prior authorization and will continue to be covered.</td>
<td></td>
</tr>
<tr>
<td>Diabetes Dipeptidyl Peptidase-4 (DPP-4) Inhibitors</td>
<td>NESINA ONGLYZA</td>
<td>JANUVIA, TRADJENTA</td>
</tr>
<tr>
<td>Diabetes Sodium-Glucose</td>
<td>FAXIGA, JARDIANE</td>
<td></td>
</tr>
<tr>
<td>Common Condition/Therapeutic Class</td>
<td>Drug Subject to Prior Authorization</td>
<td>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Diabetes</td>
<td>INVOKAMET</td>
<td>XIGDUO XR</td>
</tr>
<tr>
<td>Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor/Biguanide Combinations</td>
<td>ACCU-CHEK STRIPS AND KITS BREEZE 2 STRIPS AND KITS CONTOUR STRIPS AND KITS CONTOUR NEXT STRIPS AND KITS FREESTYLE STRIPS AND KITS All other test strips that are not ONETOUCH brand</td>
<td>ONETOUCH ULTRA STRIPS AND KITS, ONETOUCH VERIO STRIPS AND KITS</td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>ATACAND HCT EDARBI TEVETEN</td>
<td>candesartan-hydrochlorothiazide, irbesartan-hydrochlorothiazide, losartan-hydrochlorothiazide, telmisartan-hydrochlorothiazide, valsartan-hydrochlorothiazide, BENICAR HCT</td>
</tr>
<tr>
<td>Angiotensin II Receptor Antagonists/ Diuretic combinations</td>
<td>ATACAND DIOVAN EDARBI TEVETEN</td>
<td></td>
</tr>
<tr>
<td>Erectile Dysfunction</td>
<td>LEVITRA VIAGRA</td>
<td>CIALIS</td>
</tr>
<tr>
<td>Phosphodiesterase Inhibitors</td>
<td>AMITIZA</td>
<td>LINZESS</td>
</tr>
<tr>
<td>Gastrointestinal Agents</td>
<td>LUMIGAN</td>
<td></td>
</tr>
<tr>
<td>Iritable Bowel Disease – Constipation Predominant</td>
<td>GENOTROPIN NUTROPIN AQ OMNITROPE SAZEN</td>
<td>HUMATROPE, NORDTROPIN</td>
</tr>
<tr>
<td>Glaucoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostaglandin Analogis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GROWTH HORMONES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>ATACAND DIOVAN EDARBI TEVETEN</td>
<td></td>
</tr>
<tr>
<td>Angiotensin II Receptor Antagonists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>EXFORGE HCT</td>
<td>amlodipine-valasartan-hydrochlorothiazide, TRIBENZOR</td>
</tr>
<tr>
<td>Angiotensin II Receptor Antagonists/ Calcium Channel Blocker/Diuretic Combinations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>NORVASC</td>
<td>amlodipine</td>
</tr>
<tr>
<td>Angiotensin II Receptor Antagonists/ Calcium Channel Blockers</td>
<td>CARDIZEM mazim LA CARDIZE, CD cardizem LA (includes generic cardizem LA)</td>
<td>diltiazem ext-rel (except generic of cardizem LA)</td>
</tr>
<tr>
<td>Inflammatory Bowel Disease (IBD), Ulcerative Colitis Aminosalicylates</td>
<td>ASACOL HD DELZICOL</td>
<td>balsalazide, budesonide capsule, sulfasalazine, sulfasalazine delayed-rel, APRISO, LIALDA, PENTASA, UCERIS</td>
</tr>
<tr>
<td>Kidney Disease</td>
<td>FORSRENOL</td>
<td>calcium acetate, PHOSLYRA, RENVELA, VELPHORO</td>
</tr>
<tr>
<td>Phosphate Binders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis Agents</td>
<td>AVONEX EXTAVIA PLEGRIDY</td>
<td>AUBAGIO, BETASERON, COPAXONE, GILENYA, REBIF</td>
</tr>
<tr>
<td>Musculoskeletal Agents</td>
<td>AMRIX</td>
<td>cyclobenzaprine</td>
</tr>
<tr>
<td>Opioid Dependence Agents</td>
<td>ZUBSOLV</td>
<td>buprenorphine-naloxone sublingual tablet, SUBOXONE FILM</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>EUFLEXXA MONOVISC ORTHOVISC</td>
<td>GEL-ONE, HYALGAN, SUPARTZ</td>
</tr>
<tr>
<td>Viscosupplements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain and Inflammation</td>
<td>ARTHROTEC VIMOVO DUEXIS</td>
<td>celecoxib; diclofenac, meloxicam, or naproxen WITH lansoprazole, pantoprazole, omeprazole, omeprazole-sodium bicarbonate capsule, pantoprazole, DEXILANT, or NEXIUM</td>
</tr>
<tr>
<td>Nonsteroidal Anti-inflammatory Drugs (NSAIDs)/Combinations</td>
<td>FLECTOR PENNSAID NAPRELAN</td>
<td>diclofenac; diclofenac sodium solution, meloxicam, naproxen, VOLTAREN GEL</td>
</tr>
<tr>
<td>Prostate Condition</td>
<td>JALYN</td>
<td>fl Province of AVODART WITH alfluzoic acid-rel, doxazosin, tamsulosin, terazosin or RAPAFLO</td>
</tr>
<tr>
<td>Benign Prostatic Hyperplasia Agents/Combinations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transplant</td>
<td>Hecoria</td>
<td>tacrolimus</td>
</tr>
<tr>
<td>Immunosuppressants, Calcineurin Inhibitors</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Non-Sedating Antihistamines and Proton Pump Inhibitors – Coverage Changes – Fall 2015**

Currently, in order to obtain coverage for prescription drugs classified as non-sedating antihistamines (NSAs) and proton pump inhibitors (PPIs) prior authorization must be granted by MCTWF’s Utilization Review Department based on evidence of satisfaction of certain documented criteria.

**Non-Sedating Antihistamines – Effective with prescription fills on or after January 1, 2016**, due to the universal availability of over-the-counter NSAs, MCTWF coverage will cease except that those patients who have an existing MCTWF authorization as of 12/31/15 will remain covered for the remainder of the authorization period, subject, of course, to otherwise maintaining eligibility for MCTWF prescription drug benefits.

**Proton Pump Inhibitors – Effective with prescription fills on or after January 1, 2016**, patients will be allowed 90 units of generic PPIs per 365 day period without needing prior authorization. For patients requesting brand PPIs, or treatment for longer than 90 days per 365 day period, prior authorization will be required and administered by CVS/caremark to determine whether medical necessity requirements are satisfied. Patients who have an existing MCTWF authorization as of 12/31/15 will remain covered for the remainder of the authorization period, subject, of course, to otherwise maintaining eligibility for MCTWF prescription drug benefits.

**Compound Drugs – Expanded Limitations on Coverage – Fall 2015**

As stated in the spring 2015 issue of the *Messenger* effective June 2015, in an effort to promote the use of safe, effective compounds, all compound drug claims exceeding $300 are subject to review for medical appropriateness by CVS/caremark through consideration of prior authorization requests. Further all compound fills, regardless of the charge, are limited to one fill of the same compound per 34 days. The patient’s physician must contact CVS/caremark at 800-626-3046.

In light of the recent explosion in the prices charged by unscrupulous compounding pharmacies for bulk powders and proprietary compounding bases, **effective with prescription fills on or after January 1, 2016**, limitations on coverage are expanded, as follows:

- coverage will be denied for proprietary compounding bases, bulk compounding powders, and compounding kits; and
- coverage will be excluded for select topical compounded analgesics (pain patches).

**CVS/caremark’s Advance Control Specialty Formulary Program – Fall 2015**

**Effective January 1, 2016**, CVS/caremark’s Advance Control Specialty Formulary Program is expanding to cover a total of 11 therapeutic classes. As previously explained, this Program was designed to help address the extraordinary and rapidly growing cost of specialty drugs. It does so by limiting coverage to lower cost but equally effective specialty drugs in the same therapeutic class, as determined by step therapy. These therapeutic classes are:

1. Autoimmune
2. Chronic Myeloid Leukemia (CML)
3. Hematology
4. Hepatitis C
5. Growth Hormone
6. Multiple Sclerosis
7. Osteoarthritis
8. Osteoporosis
9. Prostate Cancer
10. Pulmonary Arterial Hypertension
11. Transplant

If the patient is prescribed a specialty medication and goes to a retail pharmacy, the pharmacist will ask the patient to contact CVS/caremark at 800-237-2767 to initiate a direct relationship with CVS/caremark specialty pharmacy services.

**Opioid Use and Abuse – Spring 2016**

The following text was excerpted, with permission, from a broader article entitled “Controlled Substance Strategies at CVS Health,” from its February 2016 issue of *Clinical Knowledge Management News for Clients*. Article footnotes were extensive and have been removed in the interest of space. The Fund is considering implementation of controlled substance management programs to better address this rampant problem.
Opioid Medication Uses and Risks
Prescription opioid medications are used to treat severe acute pain, such as from surgery or injury, and chronic pain from active cancer or at the end of life. Guidelines from the American Pain Society (APS) and American Academy of Pain Medicine (AAPM) state that chronic opioid therapy can also be an effective therapy for carefully selected and monitored patients with chronic noncancer pain. Some medications in this class include hydrocodone, oxycodone, morphine, methadone, buprenorphine and codeine.

However, opioid medications are associated with dependence, tolerance, abuse and risk of accidental overdose. One study found that death rates for drug overdoses involving opioids were 7.8 per 100,000 adults aged 18 through 64 years in 2013, an increase from 4.5 per 100,000 in 2003. The same study, which looked at nonmedical prescription opioid use and use disorders, also found increases in the prevalence of opioid use disorders and frequency of use during the same period although the prevalence of nonmedical use of prescription opioids decreased. Opioids can also have side effects, such as sleepiness and constipation. They can worsen pain, impair driving, and affect the immune system, and they are associated with a number of drug interactions.

Overprescribing of Controlled Substances
Overprescribing of controlled substances, such as opioids, is an area of concern. Health care providers wrote 258.9 million prescriptions for painkillers in 2012, enough for every American adult to have a bottle of these pills. While those in the United States constitute only 4.6 percent of the world’s population, they consume 80 percent of the global opioid supply and 99 percent of the global hydrocodone supply. According to the Centers for Disease Control and Prevention (CDC), overprescribing of opioids is associated with higher rates of drug overdose deaths and substance abuse treatment admissions.

In 2014, 6.5 million people aged 12 years or older reported nonmedical use of psychotherapeutic drugs—about two-thirds of those people were taking pain relievers non-medically. National Survey on Drug Use and Health data indicate that 53 percent of non-medical users of controlled prescription drugs (pain relievers, tranquilizers, stimulants and sedatives) aged 12 or older obtained the prescription drugs they most recently used “from a friend or relative for free,” and 21.2 percent reported obtaining them from “one doctor,” according to a recent report from the DEA. More than four in five of those who obtained prescription drugs from a friend or relative for free reported that their friend or relative had obtained the drugs from a single doctor. Strategies to address overprescribing are essential. For instance, the U.S. Department of Health and Human Services recommended looking at opioid prescribing practices to reduce opioid use disorders and overdose as one of the three priority areas they identified in an initiative to combat opioid abuse.

Risk Factors for Adverse Outcomes in Opioid Abuse
A number of risk factors have been associated with adverse outcomes in opioid use, such as overdose and progression to substance abuse. We can pursue improved clinical outcomes through positively impacting the following measures of controlled substance use:

- Morphine equivalent dose (MED) greater than 120 mg/day, although risk also exists at lower doses. Determining MED is the process of converting from one opioid agent to an equivalent dose of another agent or changing the route of opioid administration using morphine as the reference standard. It is used for determining the dose when a patient is on one or more opioids;
- Use of opioids for greater than 90 days;
- Multiple prescribers and pharmacies; and
- Combinations of central nervous system depressants (such as benzodiazepines and other sedatives— hypnotics, antidepressants and sleep aids—along with an opioid).

Herpes Zoster (Shingles) Vaccine – Expanded Coverage – Spring 2016
Herpes Zoster (shingles) is an acute viral infection caused by the reactivation of the varicella-zoster (chickenpox) virus acquired during childhood. Currently, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, advises covering, as a preventive benefit under the Affordable Care Act, only one dose of the shingles vaccine and only at age 60 or older. This is despite significant evidence that the incidence of shingles sharply rises beginning at age 50, and that the vaccination’s effectiveness appears to last only for approximately 5 years. The Fund’s Trustees have decided that effective May 5, 2016, for MCTWF Actives Plan participants and beneficiaries, subject to approval of physician prior authorization requests by the Fund’s Utilization Review office, coverage of shingles vaccinations is expanded to include individuals between the ages of 50 and 59 who have a history of recurring shingles infections, provided that the vaccination is administered no less than one year following the onset of the most recent shingles episode. Shingles vaccinations for such individuals will be provided as a medical benefit (subject to applicable deductibles and coinsurance charges). The Fund continues to provide, as a preventive benefit, free coverage for the first shingles vaccination administered on or after age sixty. However, coverage is expanded further to include revaccinations for all eligible participants, no more
frequently than once every five years, as a medical benefit. The foregoing applies as well to MCTWF Retirees Plan participants and eligible spouses except that coverage in all cases is provided as a medical benefit.

**CVS/caremark Standard Formulary Exclusions and Add-Backs – Fall 2016**

As was first announced in the winter 2011-2012 Messenger, MCTWF’s pharmacy benefit manager, CVS/caremark, made prior authorization for medical necessity of prescription drugs that are excluded from its Standard Formulary list a condition of coverage. The following list reflects those drugs that, effective January 1, 2017, either are newly excluded from the Standard Formulary (and therefore require prior authorization), or have been returned to it (and therefore no longer require prior authorization). CVS/caremark is notifying current utilizers and their prescribing physician of the newly excluded drugs, and is providing them with a list of covered alternative drugs that are therapeutically equivalent. Please note that generic drugs are in lowercase italics font and brand drugs are in UPPERCASE roman font. To obtain prior authorization, your physician must contact CVS/caremark at 800-626-3046. Since the full list of drugs excluded from the Standard Formulary (and therefore requiring prior authorization) has become too lengthy for publication here, the list is published on our website at www.mctwf.org (click on the Info Links page and view the list under CVS/caremark).

<table>
<thead>
<tr>
<th>Common Condition/Therapeutic Class</th>
<th>Drug Newly Excluded from Standard Formulary Effective 1/1/17 (Subject to Prior Authorization)</th>
<th>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</th>
<th>Drug Added Back to Standard Formulary Effective 1/1/17 (No Longer Subject to Prior Authorization)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergies</td>
<td>Nasal Steroid/Combinations</td>
<td></td>
<td>DYMISTA</td>
</tr>
<tr>
<td>Anti-infectives, Antivirals Hepatitis C Agents</td>
<td>DAKLINZA OLYSIO TECHNIVIE ZEPATIER</td>
<td>EPCLUSA, HARVONI, SOVALD</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>Beta Agonists, Short-Acting</td>
<td>PROVENTIL HFA, VENTOLIN HFA</td>
<td>PROAIR HFA, PROAIR RESPICLICK</td>
</tr>
<tr>
<td>Cancer</td>
<td>Chronic Myelogenous Leukemia Agents</td>
<td>GLEEVEC TASIGNA</td>
<td>imatinib mesylate, BOSULIF, SPRYCEL</td>
</tr>
<tr>
<td>Cancer Prostate</td>
<td>Hormonal Agents, Antiandrogens</td>
<td>NILANDRON XTANDI</td>
<td>bicalutamide, ZYTIGA</td>
</tr>
<tr>
<td>Cardiovascular Antilipemics HMG-CoA Reductase Inhibitors (HMGs or Statins) / Combinations</td>
<td>CRESTOR</td>
<td>atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, VYTORIN</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Potassium Supplements</td>
<td>KLOR-CON/25</td>
<td>potassium chloride liquid</td>
</tr>
<tr>
<td>Cardiovascular Pulmonary Arterial Hypertension Agents</td>
<td>OPSUMIT</td>
<td></td>
<td>LETAIRIS, TRACLEER</td>
</tr>
<tr>
<td>Carnitine Deficiency Agents</td>
<td>CARNITOR CARNITOR SF</td>
<td>levocarnitine</td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>Inhaled Antibiotics</td>
<td>TOBI TOBI PODHALER</td>
<td>tobramycin inhalation solution, BETHKIS</td>
</tr>
<tr>
<td>Depression</td>
<td>Antidepressants, Selective Norepinephrine Reuptake Inhibitors (SNRIs)</td>
<td>venlafaxine ext-rel tablet (except 225 mg)</td>
<td>duloxetine, venlafaxine, venlafaxine ext-rel capsule, PRISTIQ</td>
</tr>
<tr>
<td>Common Condition/Therapeutic Class</td>
<td>Drug Newly Excluded from Standard Formulary Effective 1/1/17 (Subject to Prior Authorization)</td>
<td>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</td>
<td>Drug Added Back to Standard Formulary Effective 1/1/17 (No Longer Subject to Prior Authorization)</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Dermatology</strong>&lt;br&gt;Miscellaneous Skin Conditions</td>
<td>ALCORTIN A&lt;br&gt;ALOQUIN&lt;br&gt;NOVACORT</td>
<td>hydrocortisone</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong>&lt;br&gt;Long Acting Insulins</td>
<td>LANTUS&lt;br&gt;TOUJEO</td>
<td>BASAGLAR, LEVEMIR, TRESIBA</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong>&lt;br&gt;Supplies, Pen Needles</td>
<td>ALLISON MEDICAL PEN NEEDLES&lt;br&gt;NOVO NORDISK PEN NEEDLES&lt;br&gt;ULTIMED PEN NEEDLES</td>
<td>BD PEN NEEDLES</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong>&lt;br&gt;Supplies, Syringes</td>
<td>ALLISON MEDICAL INSULIN SYRINGES&lt;br&gt;TRIVIDIA INSULIN SYRINGES&lt;br&gt;ULTIMED INSULIN SYRINGES</td>
<td>BD INSULIN SYRINGES</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal Agents</strong>&lt;br&gt;Irritable Bowel Disease - Constipation Predominant</td>
<td></td>
<td></td>
<td>AMITIZA</td>
</tr>
<tr>
<td><strong>Hematologic</strong>&lt;br&gt;Anticoagulants (oral)</td>
<td>PRADAXA</td>
<td>warfarin, ELIQUIS, XARELTO</td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong>&lt;br&gt;Hemophilia Agents</td>
<td>HELIXATE FS</td>
<td>KOKENATE FS</td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong>&lt;br&gt;Neutropenia Colony Stimulating Factors</td>
<td>NEUPOGEN</td>
<td>ZARXIO</td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong>&lt;br&gt;Platelet Aggregation Inhibitors</td>
<td>PLAVIX</td>
<td>clopidogrel, BRILINTA, EFFIEN</td>
<td></td>
</tr>
<tr>
<td><strong>High Blood Pressure</strong>&lt;br&gt;Beta-blocker Combinations</td>
<td>DUTOPROL</td>
<td>metoprolol succinate ext-rel with hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td><strong>Huntington’s Disease Agents</strong></td>
<td>XENAZINE</td>
<td>tetrabenazine</td>
<td></td>
</tr>
<tr>
<td><strong>Opioid Reversal Agents</strong>&lt;br&gt;Antagonists</td>
<td>EVZIO</td>
<td>NARCAN NASAL SPRAY</td>
<td></td>
</tr>
<tr>
<td><strong>Overactive Bladder/Incontinence</strong>&lt;br&gt;Urinary Antispasmodics</td>
<td>ENABLEX&lt;br&gt;GELNIQUE</td>
<td>oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trosplum, trosplum ext-rel, MYRBETRIQ, TOVIAZ, VESICARE</td>
<td>TOVIAZ</td>
</tr>
<tr>
<td><strong>Pain</strong>&lt;br&gt;Headache Agents</td>
<td>butalbital-acetaminophen-caffeine capsule</td>
<td>naratriptan, rizatriptan, sumatriptan, zolmitriptan, RELPAK, ZOMIG NASAL SPRAY</td>
<td></td>
</tr>
<tr>
<td><strong>Pain</strong>&lt;br&gt;Transmucosal Immediate-release Fentanyl Agents</td>
<td>ABSTRAL</td>
<td>fentany transmucosal lozenge, FENTORA, SUBSYS</td>
<td></td>
</tr>
<tr>
<td><strong>Pain and Inflammation</strong>&lt;br&gt;Corticosteroids</td>
<td>DEXPAK&lt;br&gt;MILLIPRED</td>
<td>dexamethasone, methylprednisolone, predisonsone</td>
<td>DUEXIS VIMOVO</td>
</tr>
<tr>
<td><strong>Pain and Inflammation</strong>&lt;br&gt;Nonsteroidal Anti-inflammatory Drugs (NSAIDs)/Combinations</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Notice of Creditable Coverage – Fall 2016
The following Notice is published in accordance with regulations promulgated by the Centers for Medicare and Medicaid Services, pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003:

Important Notice from the Michigan Conference of Teamsters Welfare Fund (MCTWF) About Your Prescription Drug Coverage and Medicare

Please read this notice carefully and keep it where you can find it. This notice has information about your current prescription drug coverage with MCTWF and about your options under Medicare’s prescription drug coverage. This information can help you decide whether or not you want to join a Medicare drug plan. If you are considering joining, you should compare your current coverage, including which drugs are covered at what cost, with the coverage and costs of the plans offering Medicare prescription drug coverage in your area. Information about where you can get help to make decisions about your prescription drug coverage is at the end of this notice. There are two important things you need to know about your current coverage and Medicare’s prescription drug coverage:

1. Medicare prescription drug coverage became available in 2006 to everyone with Medicare. You can get this coverage if you join a Medicare Prescription Drug Plan or join a Medicare Advantage Plan (like an HMO or PPO) that offers prescription drug coverage. All Medicare drug plans provide at least a standard level of coverage set by Medicare. Some plans may also offer more coverage for a higher monthly premium.

2. MCTWF has determined that the prescription drug coverage offered by all MCTWF benefit packages with prescription drug coverage, on average for all plan members, is expected to pay out as much as standard Medicare prescription drug coverage pays and therefore is considered Creditable Coverage. Because your existing coverage is Creditable Coverage, you can keep this coverage and not pay a higher premium (a penalty) if you later decide to join a Medicare drug plan.

When can you join a Medicare drug plan?
You can join a Medicare drug plan when you first become eligible for Medicare and each year from October 15th through December 7th. However, if you lose your current creditable prescription drug coverage, through no fault of your own, you will also be eligible for a two (2) month Special Enrollment Period (SEP) to join a Medicare drug plan.

What happens to your current coverage if you decide to join a Medicare Drug Plan?
If you decide to join a Medicare drug plan, under MCTWF rules you nonetheless may not drop your MCTWF prescription drug coverage. If you have both MCTWF prescription drug coverage and Medicare prescription drug coverage, MCTWF prescription drug coverage will be primary and your Medicare prescription drug plan will be secondary. If you are a COBRA beneficiary you may drop your MCTWF coverage in full, including prescription drug coverage, and enroll in a Medicare prescription drug plan. However, you will not be able to get your MCTWF COBRA coverage back later. If you do elect COBRA continuation coverage, your COBRA prescription drug coverage will be secondary to your Medicare prescription drug plan coverage. You should compare your current coverage, including which drugs are covered, with the coverage and cost of the plans offering Medicare prescription drug coverage in your area. Your current prescription drug plan provides comprehensive coverage for eligible prescription drugs, subject to preauthorization requirements for certain brand name prescription drugs and for prescription drugs within the following drug classifications: compound drugs, proton pump inhibitors (after a 90 day generic supply during a 365 day period, or if a brand is requested), selective serotonin reuptake inhibitors (brand name only), anabolic steroids, anti-obesity, ADHD/narcolepsy (age 20 and above), acne, and oral anti-fungal drugs, subject to generic and brand copays, as detailed in your Summary Plan Description booklet. Your current coverage pays for other health expenses, in addition to prescription drugs, and you will still be eligible to receive all of your current health and prescription drug benefits if you choose to enroll in a Medicare prescription drug plan.

When will you pay a higher premium (penalty) to join a Medicare Drug Plan?
You should also know that if you drop or lose your current coverage with MCTWF and don’t join a Medicare drug plan within 63 continuous days after your current coverage ends, you may pay a higher premium (a penalty) to join a Medicare drug plan later. If you go 63 continuous days or longer without creditable prescription drug coverage, your monthly premium may go up by at least 1% of the Medicare base beneficiary premium per month for every month that you did not have that coverage. For example, if you go nineteen months without creditable coverage, your premium may consistently be at least 19% higher than the Medicare base beneficiary premium. You may have to pay this higher premium (a penalty) as long as you have Medicare prescription drug coverage. In addition, you may have to wait until the following October to join.

For more information about this notice or your current prescription drug coverage…
Contact MCTWF’s Member Services Call Center at (313) 964-2400 or 800-572-7687. NOTE: You’ll get this notice each year. You will also get it before the next period you can join a Medicare drug plan, and if this coverage through MCTWF changes. You also may request a copy of this notice at any time.
For more information about your options under Medicare prescription drug coverage...

More detailed information about Medicare plans that offer prescription drug coverage is in the “Medicare & You” handbook. You’ll get a copy of the handbook in the mail every year from Medicare. You may also be contacted directly by Medicare drug plans. For more information about Medicare prescription drug coverage:

- Visit www.medicare.gov
- Call your State Health Insurance Assistance Program (see the inside back cover of your copy of the “Medicare & You” handbook for their telephone number) for personalized help
- Call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048

If you have limited income and resources, extra help paying for Medicare prescription drug coverage is available. For information about this extra help visit Social Security on the web at www.socialsecurity.gov, or call them at 1-800-772-1213 (TTY 1-800-325-0778).

Remember: Keep this Creditable Coverage notice. If you decide to join one of the Medicare drug plans, you may be required to provide a copy of this notice when you join to show whether or not you have maintained creditable coverage and, therefore, whether or not you are required to pay a higher premium (a penalty).

September 1, 2016

2017 Recommended Child, Adolescent and Adult Immunization Schedules – Spring 2017

Immunizations received in accordance with MCTWF’s approved schedules below are covered, as noted, under MCTWF Actives Plan and MCTWF Retirees Plan medical benefits, as appropriate, if received from a network provider (please refer to your schedule of benefits for specifics). These schedules follow the recommendations of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. By going to the below online links you will find valuable additional information, including the footnotes referenced in these schedules.

Recommended Adult Immunization Schedule for Adults Aged 19 Years or Older, by Vaccine and Age Group – United States 2017

![Recommended Adult Immunization Schedule](https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf)

Please refer online to https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
Daily Low Dose Cialis Coverage Now Available Without Prior – Spring 2017

Effective, April 1, 2017, prescriptions for daily low dose (2.5 mg and 5 mg) Cialis are fillable without prior authorization and without diagnosis restrictions. The quantity limitation of 6 tablets every 34 days or 20 pills every 90 days for erectile dysfunction medications no longer applies to daily low dose (2.5 mg and 5 mg) Cialis prescriptions. The quantity limitation for all other erectile dysfunction medications continues.

Coverage for Non-Insulin Syringes – Spring 2017

MCTWF pharmacy benefits have provided coverage for “insulin” syringes when they are obtained from the pharmacy with a prescription medication, but have not provided coverage for “non-insulin” syringes except when required to inject specialty medications or when pre-filled with the prescription medication.

Effective May 4, 2017, all previously non-covered non-insulin syringes prescribed by your physician will be covered, subject to your pharmacy benefit brand copayment or coinsurance charge.

Prior Authorization and 90 Day Limits for Lidocaine Prescriptions – Spring 2017

MCTWF previously informed you of its implementation of CVS/caremark’s Core Compound Strategy program to address abuses engaged in by many compounding pharmacies in the past few years. Recently, CVS/caremark has seen an emerging trend of spiking costs and quantities billed by compounding pharmacies for lidocaine and lidocaine-containing formulations, presumably to replace some of the lost revenues that resulted from the success of the program. Lidocaine has many uses but is most commonly used topically for pain (such as with injection sites or minor surgical procedures), skin ulcers, burns, abrasions or insect bites. It can also be used for pain relief in accessible mucous membranes of the oral and nasal cavities. Lidocaine is an ingredient in both FDA-approved and unapproved products.
Effective April 17, 2017, FDA-approved products that are lidocaine or lidocaine-containing formulations will be subject to a prior authorization requirement after the first month’s fill and the authorization, if approved, will be limited to up to 90 days. Prior authorization can be obtained by having your physician contact CVS/caremark at (800) 237-2767. Targeted communications were sent to affected participants and physicians to help ensure that they are aware of these changes.

**CVS/caremark Standard Formulary Prescription Drug Updates—Winter 2017 - 2018**

As was first announced in the winter 2011-2012 Messenger, MCTWF’s pharmacy benefit manager, CVS/caremark, made prior authorization for medical necessity of prescription drugs that are excluded from its Standard Formulary list a condition of coverage. The following list reflects those drugs (listed in bold), that effective January 1, 2018 are newly excluded from the Standard Formulary (and therefore require prior authorization), or have been returned to it (and therefore no longer require prior authorization). CVS/caremark has notified affected utilizers and their prescribing physician of the newly excluded drugs, and has provided them with a list of covered alternative drugs that are therapeutically equivalent. Please note that generic drugs are in lowercase italics font and brand drugs are in UPPERCASE roman font. To obtain prior authorization, your physician must contact CVS/caremark at 800-626-3046. Since the full list of drugs excluded from the Standard Formulary (and therefore requiring prior authorization) is too lengthy for publication here, the list is published on our website at www.mctwf.org (click on the Info Links page and view the list under CVS/caremark).

<table>
<thead>
<tr>
<th>Category/Therapeutic Class</th>
<th>Drug Subject to Prior Authorization</th>
<th>Recommended Alternative Generic or Brand Drugs in Therapeutic Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-infectives, Antivirals/ Hepatitis C</td>
<td>MAVYRET</td>
<td>EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI</td>
</tr>
<tr>
<td>Anti-infectives, Antibacterials/ Tetracyclines</td>
<td>MINOCIN</td>
<td>MINOCIN</td>
</tr>
<tr>
<td>Anti-infectives, Antibacterials/ Tetracyclines</td>
<td>DORYX/DORYX MPC MONODOX</td>
<td>doxycycline hyclate</td>
</tr>
<tr>
<td>Asthma or Chronic Obstructive Pulmonary Disease (COPD)/ Steroid/ Beta Agonist Combinations</td>
<td>DULERA</td>
<td>ADVAIR, BREO ELLIPTA, SYMBICORT</td>
</tr>
<tr>
<td>Cancer Prostate/ Hormonal Agents, Antiandrogens</td>
<td>NILANDRON</td>
<td>bicalutamide, XTANDI ,ZYTIGA</td>
</tr>
<tr>
<td>Cardiovascular Antilipemics/ Cholesterol Absorption Inhibitors</td>
<td>ZETIA</td>
<td>ezetimibe</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary disease (COPD)/ Anticholinergics</td>
<td>TUDORZA</td>
<td>INCRUSE ELLIPTA, SPIRIVA</td>
</tr>
<tr>
<td>Depression/ Antidepressants, Selective Norepinephrine Reuptake Inhibitors (SNRIs)</td>
<td>venlafaxine ext-rel tablet (except 225 mg), VENLAFAXINE EXT-REL TABLET (except 225 mg), EFFLEXOR XR</td>
<td>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule,</td>
</tr>
<tr>
<td>Depression and/or Schizophrenia/ Antipsychotics, Atypicals</td>
<td>ABILIFY</td>
<td>aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, LATUDA, VRAYLAR</td>
</tr>
<tr>
<td>Diabetes/ Injectable Incretin Mimetics</td>
<td>BYDUREON BYETTA TANZEUM</td>
<td>TRULICITY, VICTOZA</td>
</tr>
<tr>
<td>Diabetes/ Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors</td>
<td>JARDIANCE</td>
<td>FARXIGA, INVOKANA</td>
</tr>
<tr>
<td>Category/Therapeutic Class</td>
<td>Drug Subject to Prior Authorization</td>
<td>Recommended Alternative Generic or Brand Drugs in Therapeutic Class</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Diabetes/Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor / Biguanide Combinations</td>
<td>SYNJARDY SYNJARDY XR</td>
<td>INVOKAMET, INVOKAMET XR, XIGDUO XR</td>
</tr>
<tr>
<td>Erectile Dysfunction/Hormonal Agents, Antiandrogens</td>
<td>STENDRA VIAGRA CIALIS</td>
<td>ELELYSO CERDELGA, CEREZYME</td>
</tr>
<tr>
<td>Gauche Disease</td>
<td>butalbital-acetaminophen-caffeine capsule FIORICET CAPSULE</td>
<td>eletriptan, ergotamine-caffeine, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</td>
</tr>
<tr>
<td>Pain/Headache</td>
<td>butalbital-acetaminophen-caffeine capsule FIORICET CAPSULE</td>
<td>eletriptan, ergotamine-caffeine, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</td>
</tr>
<tr>
<td>Migraine Injectable</td>
<td>SUMAVEL DOSEPRO</td>
<td>eletriptan, naratriptan rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</td>
</tr>
<tr>
<td>High Blood Pressure/Angiotensin II Receptor Antagonists</td>
<td>ATACAND BENICAR DIOVAN EDARBI</td>
<td>candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan</td>
</tr>
<tr>
<td>High Blood Pressure/Angiotensin II Receptor Antagonist / Diuretic Combinations</td>
<td>ATACAND HCT BENICAR HCT DIOVAN HCT EDARBYCLOR</td>
<td>candesartan-hydrochlorothiazide, irbesartan-hydrochlorothiazide, losartan-hydrochlorothiazide, olmesartan-hydrochlorothiazide, telmisartan-hydrochlorothiazide, valsartan-hydrochlorothiazide</td>
</tr>
<tr>
<td>Multiple Sclerosis Agents</td>
<td>EXTAVIA</td>
<td>Glatiramer, AUBAGIO, BETASERON, COPAXONE 40 MG, GILENYA, REBIF, TECFIDERA</td>
</tr>
<tr>
<td>Narcolepsy/Wakefulness Promoters</td>
<td>NUvigil</td>
<td>armodafinil</td>
</tr>
<tr>
<td>Osteoarthritis/Viscosupplements</td>
<td>EUFLEXXA HYALGAN MONOVISC ORTHOVISC SYNVISC SYNVISC ONE</td>
<td>GEL-ONE, SUPARTZ FX</td>
</tr>
<tr>
<td>Post-Herpetic Neuralgia</td>
<td>HORZANT</td>
<td>gabapentin, GRALISE</td>
</tr>
<tr>
<td>Testosterone Replacement/Androgens</td>
<td>testosterone gel 1% ANDROGEL 1% FORTESTA NATESTO TESTIM VOGELXO</td>
<td>testosterone gel 2%, testosterone solution, ANDRODERM, ANDROGEL 1.62%</td>
</tr>
<tr>
<td>Pain/Headache</td>
<td>butalbital-acetaminophen-caffeine capsule FIORICET CAPSULE</td>
<td>eletriptan, ergotamine-caffeine, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</td>
</tr>
<tr>
<td>Migraine Injectable</td>
<td>SUMAVEL DOSEPRO</td>
<td>eletriptan, naratriptan rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</td>
</tr>
<tr>
<td>High Blood Pressure/Angiotensin II Receptor Antagonists</td>
<td>ATACAND BENICAR DIOVAN EDARBI</td>
<td>candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan</td>
</tr>
<tr>
<td>High Blood Pressure/Angiotensin II Receptor Antagonist / Diuretic Combinations</td>
<td>ATACAND HCT BENICAR HCT DIOVAN HCT EDARBYCLOR</td>
<td>candesartan-hydrochlorothiazide, irbesartan-hydrochlorothiazide, losartan-hydrochlorothiazide, olmesartan-hydrochlorothiazide, telmisartan-hydrochlorothiazide, valsartan-hydrochlorothiazide</td>
</tr>
<tr>
<td>Multiple Sclerosis Agents</td>
<td>EXTAVIA</td>
<td>Glatiramer, AUBAGIO, BETASERON, COPAXONE 40 MG, GILENYA, REBIF, TECFIDERA</td>
</tr>
<tr>
<td>Narcolepsy/Wakefulness Promoters</td>
<td>NUvigil</td>
<td>armodafinil</td>
</tr>
</tbody>
</table>
If you decide to join a Medicare drug plan, under MCTWF rules you nonetheless may not drop your MCTWF prescription drug coverage. If you have both Medicare prescription drug coverage and Medicare prescription drug coverage, MCTWF prescription drug coverage will be primary and your Medicare prescription drug coverage will be secondary. If you are a COBRA beneficiary you may drop your MCTWF coverage in full, including prescription drug coverage, and enroll in a Medicare prescription drug plan. However, you will not be able to get your MCTWF COBRA coverage back later. If you do elect COBRA continuation coverage, your COBRA prescription drug coverage will be secondary to your Medicare prescription drug plan coverage. You should compare your current coverage, including which drugs are covered, with the coverage and cost of the plans offering Medicare prescription drug coverage in your area. Your current prescription drug plan provides comprehensive coverage for eligible prescription drugs, subject to preauthorization requirements for certain brand name prescription drugs and for prescription drugs within the following drug classifications: compound drugs, proton pump inhibitors (after a 90 day generic supply during a 365 day period, or if a brand is requested), selective serotonin reuptake inhibitors (brand name only), anabolic steroids, anti-obesity, ADHD/narcolepsy (age 20 and above), acne, and oral anti-fungal drugs, subject to generic and brand copays, as detailed in your Summary Plan Description booklet. Your current coverage pays for other health expenses, in addition to prescription drugs, and you still will be eligible to receive all of your current health and prescription drug benefits if you choose to enroll in a Medicare prescription drug plan.

When will you pay a higher premium (penalty) to join a Medicare Drug Plan?

You should also know that if you drop or lose your current coverage with MCTWF and don’t join a Medicare drug plan within 63 continuous days after your current coverage ends, you may pay a higher premium (a penalty) to join a Medicare drug plan later. If you go 63 continuous days or longer without creditable prescription drug coverage, your monthly premium may go up by at least 1% of the Medicare base beneficiary premium per month for every month that you did not have that coverage. For example, if you go nineteen months without creditable coverage, your premium may consistently be at least 19% higher than the Medicare base beneficiary premium. You may have to pay this higher premium (a penalty) as long as you have Medicare prescription drug coverage. In addition, you may have to wait until the following October to join.

---

### Notice of Creditable Coverage All MCTWF Benefit Packages with Prescription Drug Coverage—Winter 2017-2018

The following Notice is published in accordance with regulations promulgated by the Centers for Medicare and Medicaid Services, pursuant to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003:

**Important Notice from the Michigan Conference of Teamsters Welfare Fund (MCTWF) About Your Prescription Drug Coverage and Medicare**

Please read this notice carefully and keep it where you can find it. This notice has information about your current prescription drug coverage with MCTWF and about your options under Medicare’s prescription drug coverage. This information can help you decide whether or not you want to join a Medicare drug plan. If you are considering joining, you should compare your current coverage, including which drugs are covered at what cost, with the coverage and costs of the plans offering Medicare prescription drug coverage in your area. Information about where you can get help to make decisions about your prescription drug coverage is at the end of this notice. There are two important things you need to know about your current coverage and Medicare’s prescription drug coverage:

1. **Medicare prescription drug coverage became available in 2006 to everyone with Medicare.** You can get this coverage if you join a Medicare Prescription Drug Plan or join a Medicare Advantage Plan (like an HMO or PPO) that offers prescription drug coverage. All Medicare drug plans provide at least a standard level of coverage set by Medicare. Some plans may also offer more coverage for a higher monthly premium.

2. **MCTWF has determined that the prescription drug coverage offered by all MCTWF benefit packages with prescription drug coverage, on average for all plan members, is expected to pay out as much as standard Medicare prescription drug coverage pays and therefore is considered Creditable Coverage.**

### When can you join a Medicare drug plan?

You can join a Medicare drug plan when you first become eligible for Medicare and each year from October 15th through December 7th. However, if you lose your current creditable prescription drug coverage, through no fault of your own, you will also be eligible for a two (2) month Special Enrollment Period (SEP) to join a Medicare drug plan.

**What happens to your current coverage if you decide to join a Medicare Drug Plan?**

If you decide to join a Medicare drug plan, under MCTWF rules you nonetheless may not drop your MCTWF prescription drug coverage. If you have both MCTWF prescription drug coverage and Medicare prescription drug coverage, MCTWF prescription drug coverage will be primary and your Medicare prescription drug plan will be secondary.

If you elect COBRA continuation coverage, your COBRA prescription drug coverage will be secondary to your Medicare prescription drug plan coverage. You should compare your current coverage, including which drugs are covered, with the coverage and cost of the plans offering Medicare prescription drug coverage in your area. Your current prescription drug plan provides comprehensive coverage for eligible prescription drugs, subject to preauthorization requirements for certain brand name prescription drugs and for prescription drugs within the following drug classifications: compound drugs, proton pump inhibitors (after a 90 day generic supply during a 365 day period, or if a brand is requested), selective serotonin reuptake inhibitors (brand name only), anabolic steroids, anti-obesity, ADHD/narcolepsy (age 20 and above), acne, and oral anti-fungal drugs, subject to generic and brand copays, as detailed in your Summary Plan Description booklet. Your current coverage pays for other health expenses, in addition to prescription drugs, and you still will be eligible to receive all of your current health and prescription drug benefits if you choose to enroll in a Medicare prescription drug plan.

### When will you pay a higher premium (penalty) to join a Medicare Drug Plan?

You should also know that if you drop or lose your current coverage with MCTWF and don’t join a Medicare drug plan within 63 continuous days after your current coverage ends, you may pay a higher premium (a penalty) to join a Medicare drug plan later. If you go 63 continuous days or longer without creditable prescription drug coverage, your monthly premium may go up by at least 1% of the Medicare base beneficiary premium per month for every month that you did not have that coverage. For example, if you go nineteen months without creditable coverage, your premium may consistently be at least 19% higher than the Medicare base beneficiary premium. You may have to pay this higher premium (a penalty) as long as you have Medicare prescription drug coverage. In addition, you may have to wait until the following October to join.

---

### Table: Recommended Alternative Generic or Brand Drugs in Therapeutic Class

<table>
<thead>
<tr>
<th>Category/Therapeutic Class</th>
<th>Drug Subject to Prior Authorization</th>
<th>Recommended Alternative Generic or Brand Drugs in Therapeutic Class (note: the below listed generics are not the direct generic equivalent of the brand drug that is subject to prior authorization)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overactive Bladder/Urinary Antispasmodics</td>
<td>DETROL LA ENABLEX OXYTROL</td>
<td>oxazepam ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRIBETIQ, TOVIAZ, VESICARE</td>
</tr>
<tr>
<td>Osteoarthritis/Viscosupplements</td>
<td>EUFLEXX MILLIVALGON MONOVISC ORTHOVISC SYNVISC SYNVISC ONE</td>
<td>GEL-ONE, SUPARTZ FX</td>
</tr>
<tr>
<td>Post-Herpetic Neuralgia</td>
<td>HORIZANT</td>
<td>gabapentin, GRATILE</td>
</tr>
<tr>
<td>Testosterone Replacement/Androgens</td>
<td>testosterone gel 1% ANDROGEL 1% FORTESTA NATESTO TESTIM VOGELX</td>
<td>testosterone gel 2%, testosterone solution, ANDRODERM, ANDROGEL 1.62%</td>
</tr>
</tbody>
</table>

---

**Please read this notice carefully and keep it where you can find it. This notice has information about your current prescription drug coverage with MCTWF and about your options under Medicare’s prescription drug coverage. This information can help you decide whether or not you want to join a Medicare drug plan. If you are considering joining, you should compare your current coverage, including which drugs are covered at what cost, with the coverage and costs of the plans offering Medicare prescription drug coverage in your area. Information about where you can get help to make decisions about your prescription drug coverage is at the end of this notice. There are two important things you need to know about your current coverage and Medicare’s prescription drug coverage:**

1. **Medicare prescription drug coverage became available in 2006 to everyone with Medicare.** You can get this coverage if you join a Medicare Prescription Drug Plan or join a Medicare Advantage Plan (like an HMO or PPO) that offers prescription drug coverage. All Medicare drug plans provide at least a standard level of coverage set by Medicare. Some plans may also offer more coverage for a higher monthly premium.

2. **MCTWF has determined that the prescription drug coverage offered by all MCTWF benefit packages with prescription drug coverage, on average for all plan members, is expected to pay out as much as standard Medicare prescription drug coverage pays and therefore is considered Creditable Coverage.**

**When can you join a Medicare drug plan?**

You can join a Medicare drug plan when you first become eligible for Medicare and each year from October 15th through December 7th. However, if you lose your current creditable prescription drug coverage, through no fault of your own, you will also be eligible for a two (2) month Special Enrollment Period (SEP) to join a Medicare drug plan.

**What happens to your current coverage if you decide to join a Medicare Drug Plan?**

If you decide to join a Medicare drug plan, under MCTWF rules you nonetheless may not drop your MCTWF prescription drug coverage. If you have both MCTWF prescription drug coverage and Medicare prescription drug coverage, MCTWF prescription drug coverage will be primary and your Medicare prescription drug plan will be secondary. If you are a COBRA beneficiary you may drop your MCTWF coverage in full, including prescription drug coverage, and enroll in a Medicare prescription drug plan. However, you will not be able to get your MCTWF COBRA coverage back later. If you do elect COBRA continuation coverage, your COBRA prescription drug coverage will be secondary to your Medicare prescription drug plan coverage. You should compare your current coverage, including which drugs are covered, with the coverage and cost of the plans offering Medicare prescription drug coverage in your area. Your current prescription drug plan provides comprehensive coverage for eligible prescription drugs, subject to preauthorization requirements for certain brand name prescription drugs and for prescription drugs within the following drug classifications: compound drugs, proton pump inhibitors (after a 90 day generic supply during a 365 day period, or if a brand is requested), selective serotonin reuptake inhibitors (brand name only), anabolic steroids, anti-obesity, ADHD/narcolepsy (age 20 and above), acne, and oral anti-fungal drugs, subject to generic and brand copays, as detailed in your Summary Plan Description booklet. Your current coverage pays for other health expenses, in addition to prescription drugs, and you still will be eligible to receive all of your current health and prescription drug benefits if you choose to enroll in a Medicare prescription drug plan.

**When will you pay a higher premium (penalty) to join a Medicare Drug Plan?**

You should also know that if you drop or lose your current coverage with MCTWF and don’t join a Medicare drug plan within 63 continuous days after your current coverage ends, you may pay a higher premium (a penalty) to join a Medicare drug plan later. If you go 63 continuous days or longer without creditable prescription drug coverage, your monthly premium may go up by at least 1% of the Medicare base beneficiary premium per month for every month that you did not have that coverage. For example, if you go nineteen months without creditable coverage, your premium may consistently be at least 19% higher than the Medicare base beneficiary premium. You may have to pay this higher premium (a penalty) as long as you have Medicare prescription drug coverage. In addition, you may have to wait until the following October to join.
For more information about this notice or your current prescription drug coverage...

Contact MCTWF’s Member Services Call Center at (313) 964-2400 or (800) 572-7687. NOTE: You’ll get this notice each year. You will also get it before the next period you can join a Medicare drug plan, and if this coverage through MCTWF changes. You also may request a copy of this notice at any time.

For more information about your options under Medicare prescription drug coverage...

More detailed information about Medicare plans that offer prescription drug coverage is in the “Medicare & You” handbook. You’ll get a copy of the handbook in the mail every year from Medicare. You may also be contacted directly by Medicare drug plans. For more information about Medicare prescription drug coverage:

- Visit www.medicare.gov
- Call your State Health Insurance Assistance Program (see the inside back cover of your copy of the “Medicare & You” handbook for their telephone number) for personalized help
- Call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048

If you have limited income and resources, extra help paying for Medicare prescription drug coverage is available. For information about this extra help visit Social Security on the web at www.socialsecurity.gov, or call them at 1-800-772-1213 (TTY 1-800-325-0778).

Remember: Keep this Creditable Coverage notice. If you decide to join one of the Medicare drug plans, you may be required to provide a copy of this notice when you join to show whether or not you have maintained creditable coverage and, therefore, whether or not you are required to pay a higher premium (a penalty).

September 1, 2017
Michigan Conference of Teamsters Welfare Fund

Opioid Utilization Management Strategy – Winter 2017-2018

Effective February 1, 2018, MCTWF’s Pharmacy Benefits Manager, CVS/caremark, is administering on MCTWF’s behalf its Opioid Utilization Management Strategy. This clinical program, which is based upon the Centers for Disease Control and Prevention’s opioid prescribing benchmarks, is designed to strike a balance between legitimate and at-risk opioid use. Improving the way opioids are prescribed through clinical practice guidelines can ensure patients have access to safer, more effective chronic pain treatment while reducing the likelihood of misuse, abuse, or overdose from these drugs. The program entails monitoring (prospective and retrospective reviews) of opioid medication utilization, prescriber management, network pharmacy evaluation and outreach, and utilization management of opioid medications as follows:

<table>
<thead>
<tr>
<th>Utilization Management of Opioids</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Morphine Milligram Equivalent (MME) Based Quantity Limits</strong></td>
</tr>
<tr>
<td>New initial limits for obtaining opioids without prior authorization up to 90 MME/day.</td>
</tr>
<tr>
<td>Quantities higher than initial limits require post-limit prior authorization; limited to a maximum of 200 MME/day.</td>
</tr>
<tr>
<td><strong>Prior Authorization Post-Quantity Limit Coverage Duration</strong></td>
</tr>
<tr>
<td>Post-limit prior authorization approvals: 1 month for acute pain; 12 months for chronic pain.</td>
</tr>
<tr>
<td>Prescriber to reassess patient response at least every three months.</td>
</tr>
<tr>
<td>Duration not limited for patients fighting cancer.</td>
</tr>
<tr>
<td><strong>Step Therapy for Extended Release/Long Acting Opioid Analgesics for Chronic Pain</strong></td>
</tr>
<tr>
<td>For extended release opioid, trial and failure of immediate release opioid is first required.</td>
</tr>
<tr>
<td>Requires prior authorization if claim history has no prior use of an immediate release opioid, or if not already stable on an extended release opioid.</td>
</tr>
<tr>
<td><strong>10-Day Supply Duration Limit For Treatment of Acute Pain</strong></td>
</tr>
<tr>
<td>Immediate release opioids for acute pain limited to 10-day supply.</td>
</tr>
<tr>
<td>Beyond 10 days, additional supply provided when coverage conditions are met through prior authorization.</td>
</tr>
<tr>
<td><strong>Increase Access to Treat Opioid Addiction</strong></td>
</tr>
<tr>
<td>Remove prior authorization (retain quantity limits) for buprenorphine combo products (buprenorphine-naloxone).</td>
</tr>
<tr>
<td>Prior authorization with quantity limits in place for buprenorphine mono products. Emergency supply is permitted while prior authorization is processed.</td>
</tr>
</tbody>
</table>

The following is excerpted from the U.S Food & Drug Administration’s website:

Transfer Unused Medicine to Authorized Collectors for Disposal
Consumers and caregivers should remove expired, unwanted, or unused medicines from their home as quickly as possible to help reduce the chance that others may accidentally take or intentionally misuse the unneeded medicine.

Medicine take-back programs are a good way to safely dispose of most types of unneeded medicines. The U.S. Drug Enforcement Administration (DEA) periodically hosts National Prescription Drug Take-Back events where collection sites are set up in communities nationwide for safe disposal of prescription drugs. Local law enforcement agencies may also sponsor medicine take-back programs in your community. [Note: For example, in Michigan, all 29 Michigan State Police posts now serve as locations to discard expired or unused medications. No appointment is necessary. This service is available Monday through Friday from 8 a.m. to 4 p.m. (excluding holidays). Be aware that medical liquids, inhalers, patches or syringes are not accepted.] Likewise, consumers can contact their local waste management authorities to learn about medication disposal options and guidelines for their area.

Another option for consumers is to transfer unused medicines to collectors registered with the DEA. Your community, authorized collection sites may be retail pharmacies, hospital or clinic pharmacies, and law enforcement locations. Some authorized collection sites may also offer mail-back programs or collection receptacles, sometimes called “drop-boxes,” to assist consumers in safely disposing of their unused medicines. Consumers can visit the DEA’s website for more information about drug disposal, National Prescription Drug Take-Back Day events and to locate a DEA-authorized collector in their area. Consumers may also call the DEA Office of Diversion Control’s Registration Call Center at 1-800-882-9539 to find an authorized collector in their community.

Disposal in Household Trash
If no medicine take-back programs or DEA-authorized collectors are available in your area, and there are no specific disposal instructions on the label, such as flushing, you can also follow these simple steps to dispose of most medicines in the household trash: mix medicines (do not crush tablets or capsules) with an unpalatable substance such as dirt, kitty litter, or used coffee grounds; place the mixture in a container such as a sealed plastic bag; throw the container in your household trash; scratch out all personal information on the prescription label of your empty pill bottle or empty medicine packaging to make it unreadable; and then dispose of the container.

VISION BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

We are pleased to formally announce that effective October 1, 2016, EyeMed Vision Care is MCTWF’s new vision benefits administrator. MCTWF has contracted with it for access to its broad Insight Network. You have received notifications from MCTWF and from EyeMed in September with updated MCTWF Networks cards and EyeMed ID cards and a list of Insight Network participating retail and independent eyewear providers situated closest to your home (you can view a comprehensive list of EyeMed Insight Network providers by linking to them on the Provider Networks page of the Fund’s website at www.mctwf.org). EyeMed’s Insight Network offers MCTWF participants and beneficiaries who have vision benefits a far larger number of optometrists and ophthalmologists and retail eyewear locations, faster lens crafting time, and equal or better vision benefits, options, and discounts than they had previously. Network retailers include SVS Vision (Teamster represented), Lenscrafters, Pearle Vision, Target Optical, Sears Optical, and JCPenney. Please note that if you already have used up your vision benefits (exam, lenses and/or frame, or contacts) for calendar year 2016, you will not be entitled to new vision benefits until January 1, 2017. However, in any year that you’ve exhausted your vision benefits, EyeMed Insight Network providers will discount their normal retail charges by 40% on each pair of complete prescription eyeglasses.

EyeMed also offers on-line eyeglass options through www.glasses.com (you also can download the glasses.com app, which uses digital try-on technology to create a 3D model of your face, to see how thousands of styles look on you from any angle) and on-line contact lens options through www.contactsdirect.com. To access either site, click on EyeMed on the Provider Networks page of the Fund’s website and then locate them at the top of the Provider Search Results page (you also will find www.eyemedlasik.com. there for in-network laser vision correction providers). Both sites price their products in accordance with the MCTWF vision benefit and provide free shipping.
### VISION BENEFITS

<table>
<thead>
<tr>
<th>EYEMED INSIGHT NETWORK COVERAGE</th>
<th>NON-NETWORK COVERAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EXAMINATION with Dilation as Necessary</strong></td>
<td>Covered in full</td>
</tr>
<tr>
<td><strong>RETINAL IMAGING</strong></td>
<td>Up to $50</td>
</tr>
<tr>
<td><strong>CONTACT LENS EXAMINATION OPTIONS</strong></td>
<td>Up to $39 copay</td>
</tr>
<tr>
<td><strong>FRAMES</strong></td>
<td>No coverage</td>
</tr>
<tr>
<td><strong>STANDARD PLASTIC LENSES - Per Pair</strong></td>
<td></td>
</tr>
<tr>
<td>Standard Contact Lens Fit and Follow-Up</td>
<td>Covered in full</td>
</tr>
<tr>
<td>Premium Contact Lens Fit and Follow-Up</td>
<td>Covered in full</td>
</tr>
<tr>
<td><strong>FRAME OPTIONS</strong></td>
<td></td>
</tr>
<tr>
<td>Standard Contact Lens Fit and Follow-Up</td>
<td>Covered in full</td>
</tr>
<tr>
<td>Premium Contact Lens Fit and Follow-Up</td>
<td>Covered in full</td>
</tr>
<tr>
<td><strong>LAMINATED AND LENTICULAR</strong></td>
<td>$42 copay</td>
</tr>
<tr>
<td>Standard Progressive Lens</td>
<td>$72 copay</td>
</tr>
<tr>
<td>Premium Progressive Lens Tier 1</td>
<td>$82 copay</td>
</tr>
<tr>
<td>Premium Progressive Lens Tier 2</td>
<td>$107 copay</td>
</tr>
<tr>
<td>Premium Progressive Lens Tier 3</td>
<td>$42 copay, then 20% discount off retail price less $120 allowance</td>
</tr>
<tr>
<td><strong>LENS OPTIONS - Per Pair</strong></td>
<td>No coverage</td>
</tr>
<tr>
<td>UV Treatment</td>
<td>$15 copay</td>
</tr>
<tr>
<td>Tint (Solid or Gradient)</td>
<td>$15 copay</td>
</tr>
<tr>
<td>Standard Plastic Scratch Coating</td>
<td>Covered in Full</td>
</tr>
<tr>
<td>Standard Polycarbonate - Adults</td>
<td>$35 copay</td>
</tr>
<tr>
<td>Standard Polycarbonate - Kids under 19</td>
<td>Covered in Full</td>
</tr>
<tr>
<td>Standard Anti-Reflective Coating</td>
<td>$40 copay</td>
</tr>
<tr>
<td>Premium Anti-Reflective Coating Tier 1</td>
<td>$55 copay</td>
</tr>
<tr>
<td>Premium Anti-Reflective Coating Tier 2</td>
<td>$68 copay</td>
</tr>
<tr>
<td>Premium Anti-Reflective Coating Tier 3</td>
<td>No coverage. Member receives 20% discount off retail price.</td>
</tr>
<tr>
<td>Polarized</td>
<td>$75 copay</td>
</tr>
<tr>
<td>Photochromatic / Transitions Plastic</td>
<td>$70 copay</td>
</tr>
<tr>
<td>High Index</td>
<td>$60 copay</td>
</tr>
<tr>
<td>Other Lens Options</td>
<td>No coverage. Member receives 20% discount off retail price.</td>
</tr>
<tr>
<td><strong>CONTACT LENSES - Materials Only</strong></td>
<td></td>
</tr>
<tr>
<td>Conventional</td>
<td>Covered up to $120, 15% discount off balance over $120</td>
</tr>
<tr>
<td>Disposable</td>
<td>Covered up to $120</td>
</tr>
<tr>
<td>Contacts Direct Benefit Booster</td>
<td>$20 additional contact lens allowance when lenses purchased through contactedirect.com</td>
</tr>
<tr>
<td><strong>LASER VISION CORRECTION - Per Eye</strong></td>
<td>Up to $80</td>
</tr>
<tr>
<td><strong>ADDITONAL BENEFIT</strong></td>
<td>Up to $80</td>
</tr>
<tr>
<td><strong>FREQUENCY</strong></td>
<td>No Coverage</td>
</tr>
</tbody>
</table>

Note: If you utilize an ophthalmologist and do not have a medical eye condition, services will be covered under the vision portion of your benefit package. To receive network-level benefits, the ophthalmologist must participate in the EyeMed Insight network. If you are being treated by an ophthalmologist for a medical condition, services will be covered under the medical
portion of your benefit package. To receive network-level benefits, the ophthalmologist must participate in the BCBS PPO network.

By clicking on EyeMed on the Provider Networks page of the Fund’s website and registering through the Member Login, you can view your vision benefits, claims, special vision offers, provider locations and wellness information.

EyeMed also has arranged for discounted hearing aids and services through Amplifon (locations are nationwide), for those who are eligible for MCTWF medical and vision benefits. To find a hearing care provider near you and schedule a hearing exam, call 844- 526 5432. These hearing benefits are covered under your medical program, so please present your Blue Cross ID card to the provider for proper claim submission.

DEATH BENEFITS – MCTWF ACTIVES PLAN

Survivor Health Benefits – Clarification – Fall 2015

MCTWF’s Survivor Health Benefits, which was announced in the fall 2014 issue of the Messenger, provides up to 36 months (subject to ongoing eligibility rules) of free medical and prescription drug coverage for all eligible spouses and dependent children of participants who die while actively covered under a MCTWF benefits package covering such benefits (through active employment, MCTWF strike coverage, MCTWF benefit bank coverage, or weekly accident and sickness benefit coverage).

However, if at the time of death the deceased participant’s employer has ceased to maintain MCTWF benefits for the deceased participant’s employee unit, his survivors will not be eligible for Survivor Health Benefits.

DEATH BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Designating and Updating Your Death Benefit Beneficiaries – Spring 2017

MCTWF’s Summary Plan Description states that death benefits will be paid to the named beneficiary most recently listed on your Enrollment Card (or for Retiree death benefits, the Death Benefit Program Election Form) or Change of Beneficiary Form and that regardless of your subsequent divorce, if your last named beneficiary was your spouse at the time of designation, your death benefits will be paid to that person if he or she claims the benefit. This is true no matter what is ordered in your judgment of divorce or provided for under State law. As an employee welfare benefit plan, MCTWF is governed by ERISA, a federal law that preempts State law in this regard and so the Summary Plan Description rules prevail. Therefore, please keep your death benefit beneficiary designation up to date. To add or change beneficiaries from those on your enrollment card, go to the Forms page of MCTWF’s website at www.mctwf.org and fill out the Change of Beneficiary form and return it to MCTWF.

ACCIDENTAL DEATH AND DISMEMBERMENT BENEFITS – MCTWF ACTIVES PLAN

Death and Accidental Death & Dismemberment Benefits Payable to Minors – Fall 2016

Effective August 4, 2016, if the named beneficiary of Death or Accidental Death and Dismemberment benefits is under 18 years of age at the time the claim accrues, the beneficiary’s claim filing deadline is the greater of 12 months following his/her 18th birthday, or the remaining time under the MCTWF Actives Plan general death benefit claim filing deadline of 36 months from the date of death.

ASSIGNMENT, SUBROGATION AND REIMBURSEMENT – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Work Related Injury/Illness – New Conditional Coverage – Fall 2015

Under MCTWF’s General Exclusions and Limitations listed in your Summary Plan Description it states in part that an injury or illness arising in the course of employment that is covered under any workers’ compensation or occupational disease law or other state law or other insurance is not covered.

However, effective August 6, 2015, once the injured party has permanently settled his claim with the responsible party by way of a “redemption order” (or similar instrument), although pre-settlement claims continue to be deemed work related, post-settlement claims are deemed non-work related and are eligible for payment if the individual is actively covered under a MCTWF benefit package. If settlement is by way of a “voluntary payment agreement” (or similar instrument), not only do pre-settlement claims continue to be deemed work related, post-settlement claims continue to be deemed work related unless such claims are time-barred from being filed under the applicable state statute. If time-barred, the claims are treated as non-work related and will be eligible for payment if the individual is actively covered under a MCTWF benefit package.
Third Party Liability Questionnaires – Spring 2016

The Fund has subrogation rights that allow it to recover against third parties the value of benefits paid by it on behalf of participants and beneficiaries in connection with injuries or illnesses incurred on-the-job, or in connection with a motor vehicle, or caused in whole or in part by other third parties. Claims are reviewed post-payment to determine whether there may be third party liability and, if so, a questionnaire is sent to the individual, inquiring how the injury or illness was sustained. This data gathering process is now handled for the Fund by Blue Cross Blue Shield of Michigan. If you receive such a questionnaire, it is important that you answer it completely and return it in the self-addressed, postage-paid envelope. Your failure to do so may result in the denial of future related claims and pursuit of recovery of those already paid.

COORDINATION OF BENEFITS – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Coordination of Benefits (COB) Rules for Employee, Spouse, and Retiree Coverage - Clarification – Fall 2015

If you and/or your eligible beneficiaries have coverage under another group health plan as well as under the MCTWF Actives Plan or the MCTWF Retirees Plan, benefits entitlement will be coordinated between the two plans.

A group benefit plan that does not have a Coordination of Benefits (COB) provision is always primary to MCTWF. If all benefit plans have a COB provision, under MCTWF rules, the primary plan is determined as follows:

- The plan covering the patient as an active employee or as a retired employee will be primary to any plan in which the patient is covered as the dependent spouse of an active or retired employee.
- The plan covering the patient as an active employee will be primary to any plan in which the patient is covered as a retiree.
- The plan covering the patient as a dependent spouse of an active employee will be primary to a plan in which the patient is covered as a dependent spouse of a retiree.

Other Group Health Insurance Coverage – Spring 2016

Health insurance plans, including the MCTWF Actives Plan and the MCTWF Retirees Plan, follow “coordination of benefits” rules for determining primary and secondary responsibility for the payment of claims when two or more plans are responsible for payment of the same claim. Accordingly, every health insurance plan seeks to maintain current information, through periodic inquiries, to ascertain whether its participants (or insureds) are covered by other health insurance. Since Blue Cross Blue Shield of Michigan has ceased making such inquiries of you on the Fund’s behalf, we must do so.

The Fund has commenced annual issuance to participants of a Coordination of Benefits Information form asking whether participants, spouses, or children are covered under other group health insurance. The forms will be mailed out throughout this year and then every twelve months to you thereafter. Please supply the requested information and mail or fax the form back to the Fund as soon as possible so that your claims can be properly adjudicated.

Coordination of Benefits for Medical Services – Rule Modification – Winter 2017-2018

Effective July 1, 2018, Part 17 of MCTWF’s SPD booklet is amended, in part, as follows: If the Fund is the Secondary Plan it will subtract the Primary Plan’s payment from the Primary Plan’s Allowed Amount (resulting in a “net allowed amount”) and, subject to the MCTWF Actives Plan or MCTWF Retirees Plan benefit package’s Deductible, Copayment and Coinsurance amounts, will pay the net allowed amount in a sum not to exceed the MCTWF Actives Plan’s or MCTWF Retirees Plan’s Allowed Amount.

HOW TO FILE A CLAIM – MCTWF ACTIVES PLAN AND MCTWF RETIREES PLAN

Time Limits for Receipt of Claim Submissions - Reminder – Spring 2017

The following is a list of claim types and current corresponding time limits for receipt:

- Claims for health, dental, and vision benefits must be received by MCTWF within 15 months following the date that the eligible expense is incurred (i.e., the date the services were rendered).

- Claims for weekly accident and sickness benefits and total and permanent disability benefits must be received within 15 months following the date that the disability is incurred (which, for this purpose, is the date of first medical service to treat the disability).
In either case, if such timely claim is incomplete, or additional information is required to adjudicate the claim, you will be given 45 days from the date of MCTWF’s request to provide the necessary additional information, regardless of the exhaustion of the 15 month time limit. If you fail to provide the requested information within the 45 day period resulting in the denial of the claim, subsequent provision of the requested information will be considered on an appeal basis only and must be received within the 180 day from the notification of the claim denial.

Claims for participant death benefits and accidental death and dismemberment benefits must be received within three years following the date of death or dismemberment. If the named beneficiary is under 18 years of age at the time the death occurs, the beneficiary’s claim must be received before the later of one year following his/her 18th birthday, or three years from the date of death.

Claims for spouse and dependent child death benefits must be received within three years after the date of death.

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT – MCTWF ACTIVES PLAN AND MCTWF RETIRES PLAN

HIPAA Notice of Privacy Practices – Fall 2016

HIPAA regulations require the triennial publication of a Plan’s HIPAA Notice of Privacy Practices. The following is MCTWF’s HIPAA Notice of Privacy Practices, last amended November 2016. It also can be found on the HIPAA Privacy Rule page of MCTWF’s website at www.mctwf.org:

Notice of Privacy Practices for Protected Health Information.
Your Information. Your Rights. Our Responsibilities.

This Notice describes how medical information about you may be used and disclosed and how you can get access to this information. Please review it carefully.

Your Rights (see below for more information on these rights and how to exercise them)
You have the right to:

- Get a copy of your health and claims records
- Correct your health and claims records
- Request confidential communication
- Ask us to limit the information we share
- Get a list of those with whom we’ve shared your information
- Get a copy of this privacy notice
- Choose someone to act for you
- File a complaint if you believe your privacy rights have been violated

Your Choices (see below for more information on these choices and how to exercise them)
You have some choices in the way that we use and share information as we:

- Answer coverage questions from your family and friends
- Provide disaster relief
- Market our services and sell your information (Please note that this Notice uses HHS prescribed model language, but MCTWF does not market or sell medical information, or use it for any purpose other than to administer its benefit plans.)

Our Uses and Disclosures (see below for more information on these uses and disclosures)

We may use and share your information as we:

- Help manage the health care treatment you receive
- Run our organization
- Pay for your health services
- Administer your health plan
- Help with public health and safety issues
- Do research
- Comply with the law
- Respond to organ and tissue donation requests and work with a medical examiner or funeral director
- Address workers’ compensation, law enforcement, and other government requests
Your Rights

When it comes to your health information, you have certain rights. This section explains your rights and some of our responsibilities to help you.

Get a copy of health and claims records
- You can ask to see or get a copy of your health and claims records and other health information we have about you. Ask us how to do this.
- We will provide a copy or a summary of your health and claims records, usually within 30 days of your request. We may charge a reasonable, cost-based fee.

Ask us to correct health and claims records
- You can ask us to correct your health and claims records if you think they are incorrect or incomplete. Ask us how to do this.
- We may say “no” to your request, but we’ll tell you why in writing within 60 days.

Request confidential communications
- You can ask us to contact you in a specific way (for example, home or office phone) or to send mail to a different address.
- We will consider all reasonable requests, and must say “yes” if you tell us you would be in danger if we do not.

Ask us to limit what we use or share
- You can ask us not to use or share certain health information for treatment, payment, or our operations.
- We are not required to agree to your request, and we may say “no” if it would affect your care.

Get a list of those with whom we’ve shared information
- You can ask for a list (accounting) of the times we’ve shared your health information for six years prior to the date you ask, who we shared it with, and why.
- We will include all the disclosures except for those about treatment, payment, and health care operations, and certain other disclosures (such as any you asked us to make). We’ll provide one accounting a year for free but will charge a reasonable, cost-based fee if you ask for another one within 12 months.

Get a copy of this privacy notice
You can ask for a paper copy of this notice at any time, even if you have agreed to receive the notice electronically. We will provide you with a paper copy promptly.

Choose someone to act for you
- If you have given someone medical power of attorney or if someone is your legal guardian, that person can exercise your rights and make choices about your health information.
- We will make sure the person has this authority and can act for you before we take any action.

File a complaint if you feel your rights are violated
- You can complain if you feel we have violated your rights by contacting us using the information on page 8.
- You can file a complaint with the U.S. Department of Health and Human Services Office for Civil Rights by sending a letter to 200 Independence Avenue, S.W., Washington, D.C. 20201, calling 1-877-696-6775, or visiting www.hhs.gov/ocr/privacy/hipaa/complaints/.

We will not retaliate against you for filing a complaint.

Your Choices

For certain health information, you can tell us your choices about what we share. If you have a clear preference for how we share your information in the situations described below, talk to us. Tell us what you want us to do, and we will follow your instructions.

In these cases, you have both the right and choice to tell us to:
- Share information with your family, close friends, or others involved in payment for your care.
- Share information in a disaster relief situation.
If you are not able to tell us your preference, for example if you are unconscious, we may go ahead and share your information if we believe it is in your best interest. We may also share your information when needed to lessen a serious and imminent threat to health or safety.

In these cases we never share your information unless you give us written permission:

- Marketing purposes. (note: MCTWF does not market information.)
- Sale of your information. (note: MCTWF does not sell information.)

Our Uses and Disclosures

How do we typically use or share your health information?

We typically use or share your health information in the following ways:

Help manage the health care treatment you receive

We can use your health information and share it with professionals who are treating you. Example: A doctor sends us information about your diagnosis and treatment plan so we can arrange additional services.

Run our organization

- We can use and disclose your information to run our organization and contact you when necessary.
- We are not allowed to use genetic information to decide whether we will give you coverage and the price of that coverage. This does not apply to long term care plans. Example: We use health information about you to develop better services for you.

Pay for your health services

We can use and disclose your health information as we pay for your health services. Example: We share information about you with your dental plan to coordinate payment for your dental work.

Administer your plan

We may disclose your health information to your health plan sponsor for plan administration. Example: Your company contracts with us to provide a health plan, and we provide your company with certain statistics to explain the premiums we charge. (note: MCTWF’s Board of Trustees is your plan sponsor.)

How else can we use or share your health information?

We are allowed or required to share your information in other ways – usually in ways that contribute to the public good, such as public health and research. We have to meet many conditions in the law before we can share your information for these purposes. For more information see: www.hhs.gov/ocr/privacy/hipaa/understanding/consumers/index.html.

Help with public health and safety issues

We can share health information about you for certain situations such as:

- Preventing disease.
- Helping with product recalls.
- Reporting adverse reactions to medications.
- Reporting suspected abuse, neglect, or domestic violence.
- Preventing or reducing a serious threat to anyone’s health or safety.

Do research

We can use or share your information for health research.

Comply with the law

We will share information about you if state or federal laws require it, including with the Department of Health and Human Services if it wants to see that we’re complying with federal privacy law.

Respond to organ and tissue donation requests and work with a medical examiner or funeral director

- We can share health information about you with organ procurement organizations.
- We can share health information with a coroner, medical examiner, or funeral director when an individual dies.

Address workers’ compensation, law enforcement, and other government requests

We can use or share health information about you:
Michigan Conference of Teamsters Welfare Fund

- For workers’ compensation claims.
- For law enforcement purposes or with a law enforcement official.
- With health oversight agencies for activities authorized by law.
- For special government functions such as military, national security, and presidential protective services.

Respond to lawsuits and legal actions
We can share health information about you in response to a court or administrative order, or in response to a subpoena.

We never share your health information for marketing purposes. We never sell your health information.

Under the HIPAA privacy and security rules, the Plan is required to comply with State laws, if any, that also are applicable and are not contrary to HIPAA (for example, where state laws may be stricter). The Plan maintains a policy to ensure compliance with these laws.

Our Responsibilities

- We are required by law to maintain the privacy and security of your protected health information.
- We will let you know promptly if a breach occurs that may have compromised the privacy or security of your information.
- We must follow the duties and privacy practices described in this notice and give you a copy of it.
- We will not use or share your information other than as described here unless you tell us we can in writing. If you tell us we can, you may change your mind at any time. Let us know in writing if you change your mind.

For more information see: www.hhs.gov/ocr/privacy/hipaa/understanding/consumers/noticepp.html.

Changes to the Terms of this Notice

We can change the terms of this notice, and the changes will apply to all information we have about you. The new notice will be available upon request, on our web site, and we will mail a copy to you.

This Notice is effective November 2016

Privacy Officer: Barbara McGuire
(313) 964-2400 ext. 202
privacyofficer@mctwf.org